Podcasts about ut southwestern medical center

Susan Matulevicius, MD, MSCS, a national expert on resilience and work-life integration, joins the Faculty Factory Podcast this week for a discussion to help us better deal with life's inevitable stumbling blocks. Dr. Matulevicius serves as Associate Dean of Faculty Wellness and is a Professor of Internal Medicine, Cardiology, at the UT Southwestern Medical Center in Dallas. To help us think about how to create professional well-being in academic medicine, she discusses the 5 Ps: Person Purpose Path Prioritization Permission “When you get down to it, our values generally align with our purpose, and it helps us refocus when we encounter those little stumbling blocks that life puts in our way,” she said. She also touches on the value of understanding your purpose in relation to Self-Determination Theory, which is an important paradigm related to this conversation. With reassurance, Dr. Matulevicius warmly reminds us midway through the conversation of something we all need to hear occasionally: “Sometimes it's okay to not be okay." “Life and work are not always predictable, and sometimes your emotions aren't predictable in the moment. It's okay to recognize that you need more support to help you through that moment,” she said.  Learn More: https://facultyfactory.org/Susan-Matulevicius

Send us a textYou need to know what AI tools your organization is working with. In this episode, Captain Integrity Bob Wade dives into AI use (Artificial Intelligence) and guardrails in healthcare with Natalie Ramello, VP, Chief Compliance & Audit Officer, UT Southwestern Medical Center. Hear why integrity is the launchpad for innovation, how to protect the data, why AI requires accountability, why AI can hallucinate, and an AI-inspired rendition of Captain Integrity's 3 Punch Points. Learn more at CaptainIntegrity.com

“I think everyone should have Lp(a) measured.”  - Dr. Ann Marie Navar   Key Resources to Go Deeper:  - Dr. Ann Marie Navar  - Lp(a)  - Get a Free Test to Check Your Lp(a) Level   - Previous episode with Dr. Navar about ApoB  About This Episode:  Listen to this replay of an important discussion about Lipoprotein(a), or Lp(a), a critical but often overlooked marker for cardiovascular health. In this episode, host Barbara Hannah Grufferman takes a deep dive with medical expert Dr. Ann Marie Navar from UT Southwestern Medical Center about why this single test could be vital for understanding your heart disease risk, especially if you have a family history of early cardiovascular disease.  Key Topics Covered:  - What Lipoprotein(a) is and how it differs from standard cholesterol measurements  - Why Lp(a) testing is particularly important for certain individuals  - The genetic nature of Lp(a) and its implications for family health  - Current treatment options and promising new therapies on the horizon  - Practical steps for discussing Lp(a) testing with your healthcare provider  Key Takeaways:  - Lp(a) is a distinct type of cholesterol particle not captured in routine lipid panels  - High Lp(a) levels significantly increase risk of heart disease and stroke  - Lp(a) levels are primarily determined by genetics and remain stable throughout life  - Current guidelines recommend universal Lp(a) testing for adults  - New treatments specifically targeting high Lp(a) levels are expected by 2026  - Managing other risk factors can help offset the risk of elevated Lp(a)  - Coronary artery calcium scoring can provide additional risk assessment  Learn More About Dr. Ann Marie Navar  Dr. Navar is a preventive cardiologist and epidemiologist at UT Southwestern Medical Center whose research focuses on cardiovascular disease prevention, risk prediction, and clinical decision-making. She is a leading expert in advanced lipid testing and cardiovascular risk assessment. This is Dr. Navar's second appearance on AGE BETTER, following her previous discussion about the ApoB test, which was one of the most down-loaded episodes in 2024.   Connect With Barbara:  Have ideas for future episodes? We'd love to hear from you!  - Email: agebetterpodcast@gmail.com  - Connect on Instagram HERE  Note: This episode is for informational purposes only and does not constitute medical advice. Please consult with your healthcare provider about your specific situation. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this second episode of a collaborative series with the AHA Women in Cardiology (WIC) Committee, CardioNerds (Dr. Gurleen Kaur and Dr. Anna Radhakrishnan) are joined by four leading experts in Cardio-Obstetrics to explore this rapidly evolving field. Dr. Rina Mauricio (Director of Women's Cardiovascular Health and Cardio-Obstetrics at UT Southwestern Medical Center), Dr. Afshan Hameed (Director of Maternal Fetal Medicine and Cardio-Obstetrics at UC Irvine), Dr. Doreen DeFaria Yeh (Co-director of the MGH Cardiovascular Disease and Pregnancy Program), and Dr. Garima Sharma (Director of Women's Cardiovascular Health and Cardio-Obstetrics at Inova) define Cardio-Ob as encompassing not only care of women during pregnancy, but also the complex decision-making that extends through the preconception and postpartum periods. From counseling patients with pre-existing or congenital heart disease before pregnancy to managing cardiovascular health during pregnancy and after delivery, they trace how the field has developed in response to the urgent need to address maternal mortality. Listeners will gain valuable insight into the multidisciplinary teamwork, patient-centered decision-making, and advocacy that drive this field - along with the importance of expanding Cardio-Ob education for clinicians and trainees, and innovations and system-level changes shaping its future. Audio editing by CardioNerds academy intern, Grace Qiu. This episode was planned in collaboration with the AHA CLCD Women in Cardiology Committee with mentorship from Dr. Monika Sanghavi.  The PA-ACC & CardioNerds Narratives in Cardiology PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron!

Rena Malik, MD, is a board-certified urologist and pelvic surgeon specializing in sexual medicine, urogynecology, hormone management, and pelvic pain. She completed her medical education at New York University Grossman School of Medicine, followed by a urology residency at the University of Chicago and a fellowship in Female Pelvic Medicine and Reconstructive Surgery at UT Southwestern Medical Center. Practicing in Newport Beach and Beverly Hills, California, with affiliations at Tibor Rubin VA Medical Center and University of Maryland Medical Center, Malik has over 10 years of experience treating conditions like urinary incontinence, overactive bladder, and sexual dysfunction.  Named the 2023 American Urological Association Young Urologist of the Year and a Top 10 Health Influencer by Men's Health in 2023, she has hundreds of millions YouTube views and over 2.5 million social media followers for her science-driven content. She hosts the Rena Malik, MD Podcast, offering expert advice on health, sex, and relationships, and has published over 80 peer-reviewed articles. Shawn Ryan Show Sponsors: Preorder Call of Duty: Black Ops 7 now - https://www.callofduty.com Buy PYSOP: Target Intelligence - https://psyopshow.com https://americanfinancing.net/srs NMLS 182334, nmlsconsumeraccess.org. APR for rates in the 5s start at 6.327% for well qualified borrowers. Call 866-781-8900, for details about credit costs and terms. https://betterhelp.com/srs This episode is sponsored. Give online therapy a try at betterhelp.com/srs and get on your way to being your best self. https://blackbuffalo.com https://meetfabric.com/shawn https://shawnlikesgold.com https://ketone.com/srs Visit https://ketone.com/srs for 30% OFF your subscription order. https://USCCA.com/srs Rena Malik Links: Linktree - https://renamalikmd.com/linktree Website - https://renamalikmd.com YT - https://www.youtube.com/@RenaMalikMD X - https://x.com/RenaMalikMD IG - https://www.instagram.com/renamalikmd Podcast - https://podcast.renamalikmd.com FP - https://www.facebook.com/RenaMalikMD TT - https://tiktok.com/@renamalikmd LI - https://www.linkedin.com/in/renadmalik Pinterest - https://www.pinterest.com/renamalikmd Threads - https://www.threads.net/@renamalikmd Sign up for Yourology Newsletter - https://newsletter.renamalikmd.com Link to schedule an appointment - https://www.renamalikmd.com/appointments In person in Beverly Hills or Newport Beach, CA and virtually in CA, FL, IL, NY, NJ, MD, TX, VA Learn more about your ad choices. Visit podcastchoices.com/adchoices

Following a fruitful European Society of Medical Oncology (ESMO) Congress 2025 for gastrointestinal malignancies, CancerNetwork® organized an X Spaces discussion hosted by 3 experts. They were Nicholas J. Hornstein, MD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health; Timothy Brown, MD, an assistant professor in the Department of Internal Medicine and the associate program director of the Hematology & Oncology Fellowship at UT Southwestern Medical Center; and Udhayvir S. Grewal, MD, an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Each doctor focused on a specific disease type, highlighting the most important abstracts in colorectal cancer, pancreatic neuroendocrine tumors (NETs), and upper gastrointestinal cancers. The Phase 3 MATTERHORN Trial (NCT04592913) Results from MATTERHORN demonstrated that adding durvalumab (Imfinzi) to 5-fluorouracil, leucovorin (folinic acid), oxaliplatin, and docetaxel (FLOT) improved overall survival (OS) compared with FLOT plus placebo in patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, regardless of pathological status.1 In the intention-to-treat population, the median OS was not reached in either arm, and the hazard ratio (HR) was 0.78 (95% CI, 0.63-0.96; P = .021). Notably, the improvement was observed regardless of PD-L1 status; in patients with PD-L1–positive disease, the HR was 0.79 (95% CI, 0.63-0.99), and in patients with PD-L1–negative disease, the HR was 0.79 (95% CI, 0.41-1.50). “This, I believe, will seal durvalumab plus FLOT as the standard of care for resectable [gastric/GEJ] cancers,” said Brown. The Observational ASPEN Study (NCT03084770) The ASPEN study showed that active surveillance was a safe approach for patients with low-grade, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors (NETs) fewer than 2 centimeters in size.2 Of the 1000 patients enrolled in the trial, 20 patients died, of whom 18 underwent active surveillance and 2 underwent surgery. Nineteen of the deaths were unrelated to pancreatic NETs; 1 death in the surgery arm was related to a pancreatic NET. After surgery, 5 patients had disease relapse or progression. With a median follow-up of 42 months (IQR, 25-60), the OS analysis showed a P value of 0.530.  “This really settles the debate on whether or not to surgically operate on patients with a [pancreatic NET] size of [fewer] than 2 centimeters and shows that active surveillance is a safe option for these patients with pancreatic NETs [fewer] than 2 centimeters in size and non-functional NETs,” said Grewal.  Data From the Phase 2/3 FOxTROT (NCT00647530) and Phase 2 NICHE-2 (NCT03026140) Trials Neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) achieved a clinically meaningful and statistically significant improvement in long-term outcomes, including responses and survival, compared with chemotherapy strategies in patients with mismatch repair deficient (dMMR) or microsatellite instability–high (MSI-H) locally advanced colon cancer.3 In NICHE-2, neoadjuvant nivolumab plus ipilimumab achieved a 3-year disease-free survival (DFS) rate of 100% compared with 80% (95% CI, 73%-85%) with all chemotherapy strategies in FOxTROT (P

Dr. Sandra Hassink is joined by Dr. Sarah Hampl, Professor of Pediatrics at Children's Mercy in Kansas City, Center for Children's Healthy Lifestyles and Nutrition, and lead author on the 2023 Clinical Practice Guideline on Obesity. Dr. Hassink is also joined by Dr. Sarah Barlow, Professor of Pediatrics at UT Southwestern Medical Center in Dallas, Texas, and executive council member on the section on obesity (SOOb). Together they discuss the 2025 AAP National Conference and Exhibition (NCE). Related Resources: • AAP National Conference and Exhibition, Website (aapexperience.org/) • AAP Section on Obesity (tinyurl.com/3rx2rm4r) • Institute for Healthy Childhood Weight, Website (tinyurl.com/yc88y53j)

  AZ Bio Week & Life Sciences Innovation w/ Joan Koerber-Walker - AZ TRT S06 EP19 (281) 10-12-2025   Things We Learned This Week AZ Bio mission to improve life and bioscience, & make AZ a Top Ten Bioscience state AZ Bio Week 2025 - Oct. - 5 Days Talks, Events & Awards AZ Advances - nonprofit donation to biotech startups Aqualung Therapeutics is treating inflammation in the lungs, get people off ventilators & save lives Calviri is working on a Vaccine to PREVENT Cancer, currently largest animal clinical trial Anuncia Medical has a Re-Flow product to help drain fluid from the brain, treats Hydrocephalus     Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   LKIN: https://www.linkedin.com/in/joankoerberwalker  www.azbio.org Bio: As President and CEO of AZBio, Joan Koerber-Walker works on behalf of the Arizona Bioscience and Medical Technology Industry to support the growth of the industry, its members and our community on the local and national level. Ms. Koerber-Walker is also a life science investor and has served on the boards of numerous for-profit and non-profit organizations. In the life science industry, Ms. Koerber-Walker serves as as Arizona's representative to the State Medical Technology Alliance (SMTA), a consortium of state and regional trade associations representing their local medical technology companies which she chaired in 2015 and  represents Arizona as a member of the Council of State Bioscience Associations (CSBA) and the Coalition of State Bioscience Institutes (CSBI). Active in the entrepreneurial and investment communities, she also serves as Chairman of the Board of the Opportunity Through Entrepreneurship Foundation which provides entrepreneurial education, mentoring and support to at-risk members of the community, on the Board of Advisors to CellTrust, Inc. which provides secure communication technology to the healthcare industry, and as Chairman of CorePurpose, Inc. which she founded in 2002. Ms. Koerber-Walker has been recognized as Executive of the Year by the Arizona Society of Association Executives, as a “Most Admired Leader” by the Phoenix Business Journal (2015),  in the pages of AZ Business Leaders (2013 thru 2020), Most Influential Women in Arizona Business (2014) and is a 2 time National Finalist for the Stevie Award which recognizes the work of women in business. Her past experience includes two years as the CEO of ASBA (the Arizona Small Business Association), service as a member of the Board of Trustees of the National Small Business Association in Washington D.C., President of the National Speakers Association/Arizona, Chair of the Board of Advisors to Parenting Arizona, the state's largest child abuse prevention organization, & much more.         AZBio:  Supporting Arizona's Life Science Industry for 19 Years (2003 – 2022) Learn more about Arizona's bioindustry: www.azbio.org | Facebook: AZBIO |Twitter: @AZBio @AZBioCEO We're part of a movement to create sustainable funding for life science innovation in Arizona. Learn more at www.AZAdvances.org  MOVING LIFE SCIENCE INNOVATIONS ALONG THE PATH FROM DISCOVERY TO DEVELOPMENT TO DELIVERY OUR VISION OF THE FUTURE: Arizona is a top-ten life science state. OUR MISSION: AZBio supports the needs of Arizona's growing life science ecosystem. The Arizona Bioindustry Association (AZBio) is a not-for-profit, 501(c)6 trade association supporting the growth of Arizona's life science sector. AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.   AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.   Arizona's bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona's universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.   Notes:   Seg 1   Biotech and life sciences industry in Arizona, has 3000 businesses and 36,000 employees. The economic impact in 2021 was $38.5 billion. AZ Bio would like to double, so by 2033, the impact would be $78 billion.   Examples of biotech companies in Arizona are Medtronic that makes medical devices, WL Gore, material sciences. Other companies in diagnostics, there are Sonoran Quest which does testing. This also Castle Bio Sciences, deals in cancer treatment. Some medicine companies are Bristol, Myers, and Calvari who deals in cancer drugs. Calvari is the bio science company of the year in 2024.   AZ Bio Science Week started in 2017. AZ Bio week starts Oct. 13 (2025) and has events daily from Monday to Friday.     Example of one of the many companies involved with AZ Bio week:   CND Life Sciences - CND's Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.   NIH - National Institute of Health gives grants or funding to universities, hospitals and even companies for medical research.   Takes time to build a medical device type product, a few years to decades.   Government is an important partner, that provides financial support. Examples are Medicare research, workforce help, and tax breaks. Many organizations like this are publicly funded with government and university help.  $25 billion in funding over the last 20 years in Arizona in bio investment. Government funded $5 billion, that's from state and federal sales tax at a penny per. $112 million funding to universities in 2022. Combination of industry, government and philanthropy. Discovery phase - university helps develop the IP and research. Technology is spun out of the university to corporate development by companies. The AZ Board of Regents owns the patents. They license the patents to companies. Then you have regulatory.  Distribution of a product. Successful products are profitable. They have a royalty that pays to the company, the university and the government. Example of this was the University of Florida created Gatorade in the 1970s and still gets royalties today. Process takes 10 to 15 years, with hundreds of people involved. Clinical trials of any type of drug takes years.   Creation of the Covid vaccine was an outlier, as many people had Covid at the time so it was very easy to put together big study groups       Seg 2   Examples of newer companies in biotech field –   Neo clinical stage company dealing in heart health with aortic artery for the abdomen.   Another new company is prim dealing in MCT deficiency, compound growth and they are in clinical and testing stages.   Drugs get tested through computer models, and then on animals. Always have to worry about safety and ethics. FDA has very strict rules. You do not put people at risk, after monitor, during test and post monitoring. There's high-level quality control.       AZ Bio has members that are in the bioscience industry with current companies   AZ Advances is about bio startups in early stage companies It's a 501 C nonprofit charity that is funding, internships, and education   Patient is not only the client, but the purpose for why biotech companies exist     Neuralink Corp. is an American neurotechnology company that has developed as of 2024 implantable brain–computer interfaces. It was founded by Elon Musk and a team of eight scientists and engineers. Neuralink was launched in 2016 and first publicly reported in March 2017.   Neuralink's first human patient, Noland Arbaugh, is an Arizona native who received his implant in January 2024 at the Barrow Neurological Institute in Phoenix. He will appear at Arizona Bioscience Week 2025     https://www.azbio.org/azbw2025     Events Summary:   Monday - Women in Biotech Leading Women: Biotech & Beyond Join us for an evening of conversation and connections with our community's leading women as we kick off Arizona Bioscience Week in style!   Tuesday - Fundraising Fundraising Strategies for Life Science Startups  A compelling narrative is crucial when you are fundraising and communicating with life science investors.  This Life Science Nation (LSN) Global Fundraising Bootcamp covers topics related to executing a successful fundraise for your startup.      Wednesday – AZ Bio awards, philanthropy, entertainment, and AZ Advances The 21st Annual AZBio Awards & AZAdvances After Party Celebrate with the Educators, Researchers, and Organizations that are making life better for people in Arizona and around the world.  Join us at the Phoenix Convention Center as we honor the 2024 AZBio Award Winners. Hundreds of health innovators and business leaders will be celebrating at the 20th Annual AZBio Awards.   Thursday -  AZAdvances   AZ Advances Health Innovation Summit This exclusive event will bring together health innovation leaders to share how are moving Arizona forward as we make life better for the people we serve.   AZ Advances: Arizonans are advancing life changing and life saving innovations along the path from discovery to development to delivery. AZAdvances is developing the funding that will help advance health innovations in Arizona today and for generations to come.  Charitable donations to the AZAdvances fund at the Opportunity Through Entrepreneurship Foundation, an Arizona based 501c3 public charity, are a way to support the creation of tomorrow's medical innovations.    Friday - Voice of the Patient Patients are the reason we do what we do.  Join the conversation on life science innovation from the patient perspective.        Seg. 3 Best of AZ Bio clips:   AZ Bio & Life Sciences Innovation w/ Joan Koerber-Walker - BRT S04 EP10 (172) 3-5-2023   Guest: Joan Koerber-Walker President and CEO, AZBio - Arizona Bioindustry Association, Inc. Chairman, Opportunity Through Entrepreneurship Foundation   Full Show: HERE     Guest: Stan Miele President & CBO Aqualung Therapeutics Corp LKIN: HERE www.aqualungtherapeutics.com   Stan Miele Bio: A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries. Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc.  He was also President of Sucampo Pharma Americas for 6 years.   He was instrumental on some key licensing agreements for Sucampo, inclusive of the agreement with Abbott Japan, and also Takeda Pharmaceuticals (now Shire).  He is actively part of the team ensuring proper execution of clinical development, manufacturing, licensing, capital funding, alliances, and ensuring Aqualung meets all critical milestones.  He will be helping the company move toward accelerating the pipeline/platform technology and moving eNamptor™ toward commercialization.   Aqualung Therapeutics  Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung's strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.   Full Show: HERE       Seg. 4 – Clips from:  Preventing Cancer with a Vaccine w/ Stephen Johnston of Calviri  - BRT S04 EP17 (179) 4-23-2023   Guest: Stephen Johnston Founding CEO, Calviri Inc.  LKIN: HERE https://calviri.com/   Bio: Chief Executive Officer & Chairman of the Board Stephen Albert Johnston is the inventor of the Calviri's central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute's Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.     Calviri Inc.  We are determined to offer humanity a better life, free from cancer. While our goal is hugely ambitious, we are intensely driven to rid the planet of worry from cancer. Calviri's mission is to provide affordable products worldwide that will end deaths from cancer. We are a fully integrated healthcare company developing a broad spectrum of vaccines and companion diagnostics that prevent and treat cancer for those either at risk or diagnosed. We focus on using frameshift neoantigens derived from errors in RNA processing to provide pioneering products against cancer. The company is a spin out of the Biodesign Institute, Arizona State University, located in Phoenix, AZ. We have the largest dog vaccine trial in the world underway at three premier veterinary universities. The five-year trial will assess the performance of a preventative cancer vaccine.   Full Show: HERE       ReFlow to Help Treat Hydrocephalus w/ Elsa Abruzzo & Mark Geiger of Anuncia Medical - BRT S04 EP23 (186) 6-11-2023     Guest: Elsa Chi Abruzzo RAC, FRAPS – President Elsa Chi Abruzzo is a medical device executive, entrepreneur, and a founding member of Anuncia, Inc., Alcyone Therapeutics, Arthromeda, Inc. and Cygnus Regulatory. Elsa has a 30+ year successful product development, operations, regulatory, quality, and clinical track record in med tech Industries. Her experience includes leadership positions at Baxter, Cordis JNJ, CryoLife, Percutaneous Valve Technologies, AtriCure, InnerPulse, Merlin MD, Sapheon, and PTS Diagnostics. Elsa earned a BS in engineering from the University of Miami in Coral Gables, FL and is regulatory affairs certified and a Regulatory Affairs Professional Society Fellow, recognized for her leadership in Regulatory and Quality by MDDI.   https://anunciamedical.com/the-anuncia-story/#team https://www.linkedin.com/in/elsachiabruzzo/   https://anunciamedical.com/ About Anuncia Conceptualized in 2014 in collaboration with Boston Children's Hospital and spun out of Alcyone Therapeutics in 2018, Anuncia's patented portfolio of technologies are intended to provide peace-of-mind through innovation. Our core ReFlow™ technology uses a simple finger depression of a soft silicone dome located under the patient's scalp to produce a noninvasive, one-way flush of the patient's own CSF directed toward the ReFlow™ catheter to restore or increase CSF flow through a non-flowing shunt and potentially avoid emergency surgery.  Learn More     The name Anuncia comes from Panthera Uncia, the species name of the snow leopard. These animals live in mountainous regions of Asia and have been called by the World Wildlife Foundation “Guardians of the Headwaters” as they roam the headwater areas of the western basins. The origin of the word hydrocephalus comes from the Greek hudrokephalon, from hudro ‘water'+ kephalē ‘head'. The snow leopard, or Guardian of the Headwaters, is a symbol of Anuncia's dedication to improve daily quality of life for the millions of underserved patients with hydrocephalus and other CSF disorders, as well as their families, who suffer from the clinical, economic, and emotional burden of repeat revision brain surgery due to VP shunt occlusions.      Full Show: HERE           Best of Biotech from AZ Bio & Life Sciences to Jellatech: HERE   Biotech Shows: HERE   AZ Tech Council Shows:  https://brt-show.libsyn.com/size/5/?search=az+tech+council *Includes Best of AZ Tech Council show from 2/12/2023      ‘Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the BRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ ‘Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/     Disclaimer: The views and opinions expressed in this program are those of the Hosts, Guests and Speakers, and do not necessarily reflect the views or positions of any entities they represent (or affiliates, members, managers, employees or partners), or any Station, Podcast Platform, Website or Social Media that this show may air on. All information provided is for educational and entertainment purposes. Nothing said on this program should be considered advice or recommendations in: business, legal, real estate, crypto, tax accounting, investment, etc. Always seek the advice of a professional in all business ventures, including but not limited to: investments, tax, loans, legal, accounting, real estate, crypto, contracts, sales, marketing, other business arrangements, etc.

Broadcast from KSQD, Santa Cruz on 9-25-2025: Dr. Dawn opens with disturbing whistleblower allegations from Patrick Chase about organ transplant corruption. He claims poor patients at Parkland Hospital were systematically denied kidneys that were redirected to wealthier patients at UT Southwestern Medical Center. In 36 documented cases, doctors rejected kidneys as unsuitable for Parkland patients, then transplanted those same organs at the prestigious academic hospital. Chase alleges financial incentives corrupt the entire system, from procurement organizations to waiting list management. She discusses widespread scientific fraud in medical journals, citing research about PLOS journal showing 45 editors facilitated acceptance of fraudulent papers at rates far exceeding chance. These editors represented only 1.3% of reviewers but were responsible for 30% of retracted articles. Paper mills now use AI to generate fake studies with fabricated data, selling authorship to academics seeking publication credits. This undermines evidence-based medicine when treatment guidelines rely on potentially fraudulent research. Dr. Dawn introduces holy basil as a sleep aid beyond melatonin, explaining how its active compound ocimum lowers cortisol and inhibits orexin pathways that promote wakefulness. Unlike melatonin which signals sleep onset, holy basil helps maintain deep sleep by preventing middle-of-night stress spikes. She recommends 500 milligrams of aqueous leaf extract, noting this Ayurvedic herb may be particularly helpful for menopausal women experiencing sleep disruption. She warns about medication-induced osteoporosis, revealing that proton pump inhibitors increase hip fracture risk by 217% after four years of use by impairing calcium absorption and triggering parathyroid hormone release. Antidepressants pose similar risks, with SSRIs increasing fracture risk by 68% and causing women to lose bone 1.6 times faster than non-users. Cancer treatments like androgen deprivation therapy cause severe bone loss, with 81% of long-term users developing osteoporosis. Dr. Dawn challenges cholesterol treatment guidelines, explaining that Quest Labs' recommendation for LDL under 100 contradicts actual medical standards. The Veterans Administration only recommends statins for LDL above 190 plus high cardiovascular risk, or 12% ten-year risk calculated using multiple factors. She criticizes the focus on cosmetic cholesterol numbers while ignoring that high-dose statins increase diabetes risk, which is a greater health threat than elevated LDL alone. A caller describes experiencing severe ear itching followed by facial puffiness after a haircut. Dr. Dawn explains this likely represents a histamine-mediated allergic reaction, possibly triggered by salon products rather than the haircut itself. She advises getting ingredient lists from the salon to identify potential allergens and notes that bilateral symptoms suggest systemic rather than contact allergy. The oral antihistamines the caller took were appropriate treatment. Another caller asks about statin use with LDL of 155, expressing concern about adverse effects. Dr. Dawn recommends calculating ten-year cardiovascular risk rather than focusing solely on LDL numbers. She explains serious statin risks including muscle breakdown and diabetes development, particularly in women. For patients with muscle pain from statins, she suggests CoQ10 supplementation, but discontinuation if symptoms persist to prevent kidney damage from rhabdomyolysis.

What happens when we trade case law for cancer care? You get one of the richest, most human conversations we've ever brewed.This week on Counsel Brew, we branch out beyond the courtroom and into the clinic with Dr. Richard Hall—a thoracic oncologist whose life's work is treating lung cancer and supporting patients through some of their toughest moments.A proud Texan and graduate of Texas A&M and UT Southwestern, Rick went on to train at the University of Virginia and the H. Lee Moffitt Cancer Center before returning to UVA, where he not only treats patients but also trains the next generation of oncologists. He's earned teaching awards, led UVA's fellowship program, and advanced cutting-edge research in immunotherapy, targeted therapies, and combination treatments.But beyond the credentials lies a doctor who knows that medicine is about people first. In this conversation, Rick opens up about: ☕ The emotional reality of delivering difficult news and how empathy and communication are as vital as any treatment. ☕ The evolution of lung cancer care, from chemotherapy to immunotherapy to antibody-drug conjugates (a “guided missile” approach to attacking tumors). ☕ Why collaboration among medical teams is just as important as collaboration in business or law. ☕ His personal journey from med school to oncology and the moments that shaped his calling.And because no Counsel Brew is complete without actual brew, we lighten things up with Rick's adventures as a self-taught barista—how chasing the perfect shot of espresso demands scientific precision in measurements and pressure—his favorite lattes, and the joy of finding balance through coffee.

In this episode of the SRNA "Ask the Expert" podcast moderated by Dr. GG deFiebre, Dr. Kyle Blackburn and Dr. Benjamin Greenberg discussed the need for updated diagnostic criteria for myelitis. Dr. Blackburn explained the term myelitis and the importance of precise terminologies for accurate diagnoses and research [00:05:10]. Dr. Greenberg elaborated on the advancements in testing and understanding of associated disorders like NMOSD and MOGAD since 2002 [00:11:10]. Both experts stated that the shift from "transverse myelitis" to "myelitis" will aid future research, treatments, and patient care [00:17:27]. They reassured patients that these changes would essentially refine their care but not alter it dramatically [00:23:40]. They encouraged patients to stay informed and communicate with their healthcare providers about these updates [00:28:58].Kyle Blackburn, MD is an Assistant Professor in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He specializes in neuroimmunology and has clinical interests in antibody-mediated neurologic disorders, including autoimmune encephalitis, epilepsy, and ataxias; neurologic complications of cancers, including paraneoplastic disorders and checkpoint inhibitor/CAR T-cell toxicity; and demyelinating disorders, including sarcoidosis, neuromyelitis optica, myelin oligodendrocyte glycoprotein (MOG)-associated disease, and multiple sclerosis. Dr. Blackburn earned his medical degree at the University of Kentucky College of Medicine. He performed his residency in adult neurology at UT Southwestern, serving his final year as Chief Resident, and stayed to complete a fellowship in neuroimmunology, during which he earned the James T. Lubin Clinician Scientist Award from the Siegel Rare Neuroimmune Association (SRNA). He joined the UT Southwestern faculty in 2020.Benjamin M. Greenberg, M.D., M.H.S. is a Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology at UT Southwestern Medical Center in Dallas, Texas. He currently serves as the Vice Chair of Translational Research and Strategic Initiatives for the Department of Neurology. He is also the interim Director of the Multiple Sclerosis Center and the Director of the Neurosciences Clinical Research Center. In addition, he serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program at Children's Medical Center.Dr. Greenberg earned his medical degree at Baylor College of Medicine before completing an internal medicine internship at Chicago's Rush Presbyterian-St. Luke's Medical Center. He performed his neurology residency at the Johns Hopkins School of Medicine. He also holds an M.H.S. in molecular microbiology and immunology from the Bloomberg School of Public Health, as well as a bachelor's degree in the history of medicine – both from Johns Hopkins. Prior to his recruitment to UT Southwestern in 2009, Dr. Greenberg was on the faculty of the Johns Hopkins Division of Neuroimmunology, serving as the Director of the Encephalitis Center and Co-Director of the nation's first dedicated Transverse Myelitis Center.Dr. Greenberg splits his clinical time between adult and pediatric patients at William P. Clements Jr. and Zale Lipshy University Hospitals, Parkland, and Children's Medical Center. His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections. He also coordinates clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients. 00:00 Introduction00:58 Overview of Myelitis and Diagnostic Criteria02:57 Historical Context and Importance of Updated Criteria05:10 Challenges with Current Terminology11:10 Changes in Understanding and Diagnostic Approaches17:27 Implications for Patients and Clinical Practice23:40 Impact on Research and Future Directions28:58 Patient Advocacy31:17 Conclusion

In this episode of Perimenopause: Head to Toe, Dr. Rachel Pope is joined by expert dermatologist Dr. Melissa Mauskar, who dives into how perimenopause and menopause affect our skin. From changes in the face to thinning skin, Dr. Mauskar explains why skin and hair transformations during this time are not only inevitable but also manageable.Dr. Mauskar is an Associate Professor in the Departments of Dermatology and OB-GYN at UT Southwestern Medical Center. She specializes in dermatology, with a focus on vulvar health and dermatologic changes that come with different stages of a woman's life.In this episode, you'll learn: How estrogen, progesterone, and testosterone affect your skin. Why you might notice acne, dryness, or thinning hair in your 40s and beyond. The importance of topical estrogen for maintaining skin thickness. How perimenopause might trigger or worsen conditions like eczema, psoriasis, and even melasma. Tips for preventing skin aging, including the importance of sunscreen and good skincare routines.If you've noticed changes in your skin, this episode offers expert advice on how to address them and what you can do to prevent further damage.About Dr. Mauskar:Dr. Melissa Mauskar is an expert in dermatology and vulvar health, with extensive experience in addressing the skin changes that women experience during perimenopause and menopause. She is the founder of the Vulvar Health Program at UT Southwestern and frequently presents at symposia on women's health dermatology.

Dean's Chat hosts, Drs. Jeffrey Jensen and Johanna Richey, welcome Dr. Katerina Grigoropoulos to the podcast! This is a Part 1 episode, we hardly touched on Podiatry! This episoed is sponsored by Bako Diagnostics! Dr. Grigoropoulos is a board-certified podiatric physician specializing in diabetic limb salvage and wound care at the Weil Foot and Ankle Institute in Illinois. She completed her fellowship in Diabetic Limb Salvage at UT Southwestern Medical Center and her residency at Loyola University Medical Center/Hines VA Hospital. Dr. Grigoropoulos currently serves as a board member and executive secretary for the American Board of Podiatric Medicine, where she also contributes as social media sub-chair and sits on the public outreach and member newsletter committees. She is the founder of Sole Fit, a nonprofit initiative dedicated to providing new shoes to underserved children. Outside of medicine, Dr. Grigoropoulos blends creativity with service as the founder of MediThings, a medical-themed Etsy shop, and is a recent graduate of Chicago's Second City improv comedy program. Enjoy!

Amanda Ben Simon, MMS, PA-C, speaks with Sam, Miles, and Chuck about her role as co-director of the APP Fellowship Program at UT Southwestern Medical Center in part 1.

Ms. Kim Woofter and Dr. John Cox discuss the latest updates to the evidence-based standards on oncology medical homes developed by ASCO and COA. These standards serve as the basis for the ASCO Certified program. They share the new and revised standards around topics including the culture of safety and just culture in oncology practice, geriatric assessment and geriatric assessment-guided management, and multidisciplinary team management. They expand on the importance of these standards for clinicians and oncology practices to ensure every patient receives optimal care. Read the complete standards, “Oncology Medical Homes: ASCO-Community Oncology Alliance Standards Update” at www.asco.org/standards. TRANSCRIPT These standards, clinical tools, and resources are available at www.asco.org/standards. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the JCO Oncology Practice, https://ascopubs.org/doi/10.1200/OP-25-00498 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Ms. Kim Woofter, a registered nurse in practice leadership and administration from AC3 Inc in South Bend, Indiana, and Dr. John Cox, a medical oncologist and adjunct faculty member from UT Southwestern Medical Center in Dallas, Texas, co-chairs on "Oncology Medical Homes, American Society of Clinical Oncology – Community Oncology Alliance Standards." Thank you for being here today, Ms. Woofter and Dr. Cox. Dr. John Cox: You bet. Ms. Kim Woofter: Thank you. Brittany Harvey: And then before we discuss these standards, I'd just like to note that ASCO takes great care in the development of its standards and ensuring that the ASCO Conflict of Interest Policy is followed for each guidance product. The disclosures of potential conflicts of interest for the expert panel, including Dr. Cox and Ms. Woofter, who have joined us here today, are available online with the publication of the standards in JCO Oncology Practice, which is linked in the show notes. So then, to dive into what we're here today to talk about, Dr. Cox, could you start us off by explaining what prompted an update to these ASCO-COA standards and what the scope of this update is? Dr. John Cox: Well, the ASCO-COA standards relative to defining and outlining Oncology Medical Home were initially published four or five years ago. At the time, we planned a regular update of the standards. So, in essence, this is a planned update. The whole program is built on the idea of continuous improvement. So, this update and future updates are prompted and defined by our literature, our science, the science of care delivery, and new developments and insights gained from studies and evaluations of care delivery methods, and informed by the practice. These standards are in place to underpin a program of care delivery by ASCO, the ASCO Certified, and as practices engage in this program, we are learning from them. The whole idea is to enlarge and improve how patients are cared for in practice. Brittany Harvey: Absolutely. It's great to have this iterative process to continue to review the evidence and update these standards that form the basis for ASCO Certified. So then, following that background, Ms. Woofter, I'd like to review the key points of the revised standards for our listeners. First, how do the revised standards address the culture of safety and just culture in oncology practice? Ms. Kim Woofter: I think safety is of utmost importance to all of us. So let me say that first and foremost. And what we know in oncology is our QOPI standards already address safety in the infusion suite process. So, safe delivery of chemotherapy agents and antineoplastics. It also talked about near misses and medication errors - absolutely essential, for sure. But what we need to do is look at a more systemic approach to safety because we know is processes throughout an organization they'll often cause you trouble. To do that, we know you need what we call a just culture, which is a very common term in today's workplace. But what it really means is it's a culture of open reporting of any potential for error, any potential for malfunction, and it can be in any place in the organization. So, what we are doing in our new standard is to say, look at your entire processes throughout the organization, and approach that in an open-minded way so that people don't feel scared to report things, and it's a really positive approach to intervening early and making sure that errors don't occur anywhere in the workplace. Brittany Harvey: Taking that systemic approach to look at overarching processes seems really key to ensuring safety in oncology practices. So then, the next new section, Dr. Cox, what are the new OMH standards surrounding geriatric assessment and geriatric assessment–guided management? Dr. John Cox: This is a challenging update for our standards. As many folks in practice recognize, there is a deep literature on recognizing the geriatric population in oncology. Geriatric - those in my age group over age 60, 65 - make up the majority of cancer patients in this country. And yet, there are many aspects that should be taken into account as you address treatment decisions in this population. ASCO's recognized this. There has been a guideline previously on geriatric assessment. It's been updated, and we really felt it's time that it be incorporated in any iteration of what oncology care delivery means, so, within the oncology medical home standards. In short, what the standard outlines is that practices that are using these standards, that are using this benchmark, should have a geriatric assessment for patients within the practice care and use that information to guide management. Now, the standard allows wide exploration of how practices meet this standard, but it really puts on the table that if an oncology practice in the United States, or anywhere in the world really, is adhering to a good practice, that they're going to include and recognize these assessments in practice. Ms. Kim Woofter: I would like to add that this is a highly discussed and reviewed standard. Many of our community practices were concerned that they would have the time and manpower to perform this assessment. We all know it reduces toxicities if done appropriately at treatment planning, and so the outcomes are better. And we really left it to the practices to define how they're going to implement it, understanding that it will evolve to every single patient, but maybe day one, it was a step approach to be able to implement. So, I was really proud of the team that - the expert panel - that said, okay, let's step into this, but we do think it's essential. Brittany Harvey: Absolutely. It's important to recognize that practices may have limited resources and time, and implementing it in the way that makes sense for them allows this to be a standard that can be used in practice. And it's great to have this geriatric assessment guideline integrated into these standards to improve care delivery. And we can provide a link to that guideline in the show notes of this episode as well (Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update). So then, following that section of the standards, Ms. Woofter, how do the updated standards now address multidisciplinary team management? Ms. Kim Woofter: Well, we address multidisciplinary team management in a more comprehensive way in the updated standard. We always thought that that was a critical piece when doing treatment planning, and we kind of highlighted it in a bigger way, understanding that not everybody has the same resources available at the time of treatment planning. And again, this was a much-discussed standard, in that that multidisciplinary team approach doesn't necessarily have to be in a tumor board or a prospective analysis of every case. It is actually a conversation between specialists, between the surgeon and pathologist and the medical oncologist. And we are saying, do what works for you, but we know that that team approach, every specialty coming to the table at time of treatment planning, truly provides better outcomes for our patients. And so we kind of reiterated that, understanding that again, it doesn't have to be a formal tumor board, but it has to be a dialogue between specialties. And we highlighted that again in the new standard. Brittany Harvey: Open communication of all team members is really critical to providing optimal care. Dr. Cox, I'd like to ask you, in your view, how will these updated standards impact both clinicians and oncology practices? Dr. John Cox: Well, our whole goal with discussing a comprehensive care model for oncology practice is to have a benchmark, to have an iteration of what good oncology care delivery looks like. So, our hope is that practices, all practices, whether you're participating formally in ASCO Certified, the marquee quality program for ASCO, or if you are simply running a practice or a team within an academic environment or institutional environment, these standards are to apply across the board wherever oncology is practiced - that you can look at these standards as a benchmark and compare what you are doing in your practice and where are the gaps. So ideally, we drive improved care across the board. You know, one thing I've learned over the last couple of years as ASCO Certified is getting spun up and using and implementing these standards, is practices are remarkably innovative. We've learned a lot by seeing how pilot practices have met the standards, and that's gone into informing how we can improve care delivery for all of our practices and, importantly, for the team members who are delivering this care. The fourth rail of burnout and the like is inefficiency that occurs in practice. And when you know you've got a good, spun-up, effective team, less burnout, less stress for practice. I hope clinicians and oncology practices will use this to help drive improvements in their care and gain insight into how they can approach practice problems in a better way. Kim, you've been leading practices. I have to ask you, your thoughts in leaning into this question. Ms. Kim Woofter: I think very well said, I will say that first. And what I love about this is for practice leaders who are new to our ecosystem, if you will, they need a playbook. It's “Where do I begin?” And Dr. Cox said it very well, no one does everything perfectly day one, but it's a step-by-step self-assessment approach to say, “How do I get to this gold standard?” I really love the standards because they are very comprehensive, everything from treatment planning to end of life. So it's the spectrum of the care we deliver in the oncology setting. So as a leader and an administrator, it is the standard I want all of my departments to understand, adhere to, and engage, and be excited about. We now have a baseline approach, and what's even more important, these standards will evolve as our intelligence evolves, as literature evolves. It's a system that will always grow and change, and that's what we love about it. It's not a one-and-done. So, I'm very proud of the fact that it gives them a road map. Brittany Harvey: Yes, these evidence-based standards provide a critical foundation for practices in ASCO Certified, for those team members you mentioned, and for quality improvement beyond just those individuals and practices as well. So then finally, to wrap us up, Ms. Woofter, what do these revised standards mean for patients receiving cancer treatment? Ms. Kim Woofter: Well, I think that's the most exciting part, is we all do this for our patients and the best outcomes for our patients and the best treatment plans for our patients and their families. And these standards, that is their core, their absolute core. So what it's going to do for a patient is they can say, “Am I at a practice that implements ASCO standards?” And if that is a ‘yes', there's a confidence that, “I am in an evidence-based medicine thinking practice, I have a team around me, they will care for me not only at time of treatment planning but at the time of end of life, they will help me be part of that decision-making, and they will give me resources available to me in my community.” So, it is a true comprehensive approach. As a patient, I have that comfort, that it is bigger than just a great doctor. It is a great team. As a patient, that would be very important to me and important to my family. That being said, Kim Woofter would love every practice to be ASCO Certified. Understanding that that isn't feasible day one, just to know that the practice is implementing and engaging the standards is the great place to start. Every patient can't go to an ASCO Certified practice day one, but our dream would be that everyone would adhere to those standards, engage those standards, believe them, educate their staff on what they mean, so that patient outcomes and satisfaction will be optimized for everyone. The other piece to this that we all know is if you give evidence-based medicine, cost-effective, efficient care, it's better for the system as a whole. And I'm not saying that insurance is our driver - certainly patient outcomes are our driver - but the whole ecosystem of oncology benefits when you do the right thing. Dr. John Cox: It's hard to add anything to Kim's good statements, but I just highlight that this whole area began with the patient-centered medical home, and every time we've met, patients and how we deliver care to patients is top of mind. I think that reflects our community. It reflects oncology as a whole. I don't know any oncologist or practice that is focused on anything else as the prime goal. Brittany Harvey: That's what I was just going to say. The ultimate goal here is to provide patient-centered care across where every single patient is receiving treatment and at every stage of that treatment. So, I want to thank you both so much for your work to update these standards, to review the evidence, and discuss with the experts on the panel to come up with the solutions that will help drive quality improvement across care delivery. So, thank you for that, and thank you for your time today, Dr. Cox and Ms. Woofter. And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the complete standards, go to www.asco.org/standards. You can also find many of our standards and interactive resources in the free ASCO Guidelines app, which is available on the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast, and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

SPONSORS: 1) MANDO: Control Body Odor ANYWHERE with @shop.mando and get 20% off + free shipping with promo code JULIAN at https://shopmando.com ! #mando (***TIMESTAMPS in description below) ~ Dr. Kenneth Dekleva is a former physician-diplomat with the U.S. State Department and a Professor of Psychiatry at UT Southwestern Medical Center. He is also a senior fellow at the George H. W. Bush Foundation for U.S.-China Relations and the author of two novels, The Negotiator's Cross and The Last Violinist. PATREON: https://www.patreon.com/JulianDorey KEN's LINKS - IG: https://www.instagram.com/thecipherbrief/# - X: https://x.com/thecipherbrief - WEBSITE: https://www.thecipherbrief.com/experts/kenneth-dekleva - KEN WORK: https://www.blackwoodadvisorysolutions.com/ FOLLOW JULIAN DOREY INSTAGRAM (Podcast): https://www.instagram.com/juliandoreypodcast/ INSTAGRAM (Personal): https://www.instagram.com/julianddorey/ X: https://twitter.com/julianddorey JULIAN YT CHANNELS - SUBSCRIBE to Julian Dorey Clips YT: https://www.youtube.com/@juliandoreyclips - SUBSCRIBE to Julian Dorey Daily YT: https://www.youtube.com/@JulianDoreyDaily - SUBSCRIBE to Best of JDP: https://www.youtube.com/@bestofJDP ****TIMESTAMPS**** 00:00 – Ken's Past Guests, Role in State Admissions, Starting in Moscow, Truth About US Diplomats Abroad 09:23 – Intro to Psychiatry, Jim Grigson, Forensic Evaluation Techniques 20:45 – Ken's Most Intense Case, Prison Psychiatry Reality, Core Philosophy: “Nothing Human is Alien,” Language Shifts in Interviews 32:45 – Having Empathy for Monsters, Emotional Toll, Testifying in Child Abuse Trials, Evaluating Inmates for Release 41:24 – Causes of Predatory Urges, Shocking Classmate Reveal, Reconciling Faith with Catholic Abuse Scandals 49:33 – POW Camp Stories, Parents Meeting Post-WWII, Love for Language and History 57:35 – Why Psychiatry, Ken's Biggest Influence, Most Brilliant Interviewer Ever Met 01:07:31 – Trait of Elite Interviewers, Joining State Department 01:15:47 – First Day in Moscow, Love for Russia, Stress of Diplomatic Work 01:26:41 – Why People Distrust Psychiatrists, Balancing Career & Marriage Abroad 01:32:51 – Benefits for Kids Raised Overseas 01:37:06 – Havana Diplomats, Monthly Parties, Falling Into Geopolitics 01:47:49 – Presenting with Jerrold Post, Karadžić's Shift, T4 Program, Why Humans Commit Atrocities 01:59:02 – Studying Putin, Evil in Human Nature, Social Media's Dark Path 02:03:27 – Challenging Radical Beliefs, Stalin's Hero Revival, Is Kim Jong Un Rational?, What Worries Ken 02:18:01 – Profiling Xi Jinping, His Father's Story, Rumors of Xi's Fall, China's AI Race 02:26:25 – Retaining Foreign Talent, New Cold War, Kai-Fu Lee, National Space Heroes 02:35:32 – The Most Evil Mind Ken Studied, Guardrails for Social Media, Youth Mental Health, COVID Fallout 02:45:52 – Staying Tied to Government, Working with Cancer Patients, Human Side of Medicine, Does Ken Fear Death? CREDITS: - Host & Producer: Julian Dorey - Producer & Editor: Alessi Allaman - https://www.youtube.com/@UCyLKzv5fKxGmVQg3cMJJzyQ Julian Dorey Podcast Episode 321 - Ken Dekleva Music by Artlist.io Learn more about your ad choices. Visit podcastchoices.com/adchoices

Feeling adventurous but not sure how to travel with your psoriasis and psoriatic arthritis? Listen as certified physician assistant Rosemary Son offers tips to help make your care easier while traveling near or far.        Join hosts LB Herbert and Kaitlin Walden as they talk tips for making travel easier whether in the US or abroad with certified Physician Assistant Rosemary Son from UT Southwestern Medical Center. Listen in as they discuss what to pack, keeping medications including biologics cool, where to find help if needed, tips for navigating airline travel, vaccines for traveling abroad, managing travel stress, infection precautions, and more. This episode offers information to help you prepare in advance for that trip of a lifetime while maintaining management of your psoriasis and psoriatic arthritis so you can feel free to live your life to its fullest. Timestamps: ·       (0:00)  Intro to Psoriasis Uncovered & guest welcome certified Physician Assistant Rosemary Son. ·       (2:43)  Tips for keeping medications (including biologics) cool when traveling in hot weather.  ·       (5:37)  Types of skin and pain management products to pack. ·       (8:41)  Where to find help for psoriatic disease if needed in unfamiliar places. ·       (10:43) Preparing for airline travel including liquid limitations and developing a “psoriasis passport”. ·       (14:33) Travel to other countries and how to find over-the-counter medications if needed. ·       (16:43)  Vaccine recommendations for out of the country travel. ·       (19:02)  Cold weather protection recommendations. ·       (21:27)  Precautions for reducing risk of infection and should you purchase travel insurance. ·       (24:17)  Tips for managing stress as a disease trigger while traveling. ·       (28:56)  What to avoid when traveling. ·       (31:36)  Live life to the fullest with psoriatic disease and enjoy the adventure travel offers. 3 Key Takeaways: ·       Managing psoriasis and psoriatic arthritis while traveling near or far is possible with advance preparation and use of precautions to help avoid stress associated with travel in changing environments. ·       What and how you pack is key to reducing potential health issues that occur while traveling. ·       A “psoriasis passport” or letter from your physician and a list of generic names for your medications can make travel in and out of the country easier. Guest Bio: Rosemary Son, M.P.A.S., PA-C, RDN is a board-certified physician assistant in the Department of Dermatology at the University of Texas (UT) Southwestern Medical Center and Parkland Health and Hospital System. As a dual-certified Physician Assistant and Registered Dietitian with over a decade of experience in dermatology, Rosemary has a passion for treating complex inflammatory skin diseases such as psoriasis, atopic dermatitis, hidradenitis suppurativa, as well as, treating diseases that impact skin of color, and identifying social determinants of dermatologic health. She also has a personal passion for travel. Ms. Son is a Director at Large and member of the Society of Dermatology Physician Assistants and the American Academy of Physician Associates serving as a liaison to the American Academy of Dermatology. Resources: Ø  Taking Care of Your Skin in the Summer  Ø  Patient Navigation Center

Send us a textHow our biological clocks shape biology from the molecular to behavioral level.Episode Summary: Dr. Joseph Takahashi discusses circadian rhythms, exploring their biological basis, from molecular mechanisms to their impact on metabolism and health; the discovery of circadian clock genes; role of the suprachiasmatic nucleus, and how light, feeding, and oxygen influence these rhythms. The conversation highlights practical implications, such as the effects of artificial light and meal timing on health, and touches on emerging research linking stronger circadian clocks to longevity.About the guest: Joseph Takahashi, PhD is a renowned neuroscientist at UT Southwestern Medical Center, where he leads research on circadian clock genes.Discussion Points:The suprachiasmatic nucleus in the hypothalamus acts as the brain's central clock, syncing with light via the retina.Key circadian genes like CLOCK and BMAL regulate thousands of genes, especially those involved in metabolism, impacting health outcomes.Internal desynchronization, when brain and organ clocks misalign (e.g., from eating at night), can lead to metabolic issues like pre-diabetes.In mice, eating at the right time (night for nocturnal animals) extends lifespan by up to 35% under caloric restriction, compared to 10% with spread-out feeding.Artificial light, especially blue light at night, disrupts melatonin and circadian rhythms, while natural sunlight supports healthy eye development.Melatonin, a darkness-signaling hormone, is best for resetting rhythms (e.g., jet lag) at low doses, not as a sedative, and U.S. supplements vary widely in quality.Oxygen-sensing proteins interact with circadian clock components, hinting at links between altitude, metabolism, and health.Learning and memory show diurnal variations, with better performance at certain times, influenced by circadian modulation of synaptic activity.A stronger circadian clock, created genetically in mice, led to 16% longer lifespan and resistance to weight gain (unpublished research).Related episode:M&M 202: Why Do Animals Sleep? | Vlad Vyazovskiy*Not medical advice.Support the showAll episodes, show notes, transcripts, and more at the M&M Substack Affiliates: KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off Readwise: Organize and share what you read. 60 days FREE through link SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. MASA Chips—delicious tortilla chips made from organic corn & grass-fed beef tallow. No seed oils or artificial ingredients. Code MIND for 20% off For all the ways you can support my efforts

This episode of “In the Know” features conversations with Chief Medical Executive Dai Chung, M.D., and S. Kamal Naqvi, M.D., Pediatric Pulmonologist and Sleep Medicine Physician at Children's Health and Professor at UT Southwestern Medical Center, as well as Seckin Ulualp, M.D., Pediatric Otolaryngologist (ENT) at Children's Health and Professor at UT Southwestern Medical Center. Together, they discuss advancements in sleep solutions for pediatric patients at the Sleep Disorders Center at Children's Health.Children's Health is committed to making life better for children. As one of the largest and most prestigious pediatric health care providers in the country and the leading pediatric health care system in North Texas, Children's Health cares for children through more than 900,000 patient visits each year.

This episode of “In the Know” features conversations with Chief Medical Executive Dai Chung, M.D., and S. Kamal Naqvi, M.D., Pediatric Pulmonologist and Sleep Medicine Physician at Children's Health and Professor at UT Southwestern Medical Center, as well as Seckin Ulualp, M.D., Pediatric Otolaryngologist (ENT) at Children's Health and Professor at UT Southwestern Medical Center. Together, they discuss advancements in sleep solutions for pediatric patients at the Sleep Disorders Center at Children's Health.Children's Health is committed to making life better for children. As one of the largest and most prestigious pediatric health care providers in the country and the leading pediatric health care system in North Texas, Children's Health cares for children through more than 900,000 patient visits each year.

In this episode of SurgOnc Today, Dr. Miral Grandhi of Rutgers University and Dr. Neha Lad of Mount Sinai Medical Center—both members of the HPB Disease Site Working Group—provide a curated summary of the most impactful hepato-pancreato-biliary malignancy papers presented at the Society of Surgical Oncology's 2025 Annual Meeting in Tampa, Florida. The discussion is moderated by Dr. Patricio Polanco of UT Southwestern Medical Center, who also serves as Vice Chair of the HPB Disease Site Working Group.

Dr. Shaalan Beg and Dr. Kristen Ciombor discuss practice-changing studies in GI cancers and other novel treatment approaches that were presented at the 2025 ASCO Annual Meeting. Transcript Dr. Shaalan Beg: Hello, I'm Dr. Shaalan Beg, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas, Texas. There were some remarkable advances in gastrointestinal cancers that were presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Kristen Ciombor to discuss some exciting GI data. Dr. Ciombor is the Ingram Associate Professor of Cancer Research and a co-leader of Translational Research and the Interventional Oncology Research Program at the Vanderbilt Ingram Cancer Center. Our full disclosures are available in the transcript of this episode. Dr. Ciombor, it's great to have you on the podcast today. Dr. Kristen Ciombor: Thanks, Dr Beg. It's great to be here. Dr. Shaalan Beg: Alright, let's kick it off. Big year for GI cancers. We'll start off with LBA1. This was the ATOMIC study sponsored by NCI and the National Clinical Trials Network (NCTN) and the Alliance group. This is a randomized study of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for stage III mismatch repair deficient colorectal cancer. Dr. Kristen Ciombor: I think this study was really definitely practice-changing, as you can tell because it was a Plenary. But I do have some concerns in terms of how we're actually going to implement this and whether this is the final answer in this disease subtype. So, as you said, the patients were enrolled with stage III resected mismatch repair deficient colon cancer, and then they were randomized to either modified FOLFOX6 with or without atezolizumab. And that's where it starts to become interesting because not many of us give FOLFOX for 6 months like was done in this study. Obviously, the study was done over many years, so that was part of that answer, but also the patients received atezolizumab for a total of 12 months. So the question, I think, that comes from this abstract is, is this practical and is this the final answer? I do think that this is practice-changing, and I will be talking to my patients with resected mismatch repair deficient colon cancer about FOLFOX plus atezolizumab. I think the big question is, do these patients need chemotherapy? And can we do a neoadjuvant approach instead? And that's where we don't have all the answers yet. Dr. Shaalan Beg: Yeah, but it has been great to see immunotherapy make its way into the adjuvant space after having made such a big impact in the metastatic space, but still some unanswered questions in terms of the need for chemotherapy and then the duration of therapy, which I guess we'll have to stay tuned in for the next couple of years to to get a lot of those questions answered. Dr. Kristen Ciombor: Yeah, but a big congratulations to the study team, to the NCTN, the NCI. I mean, this is really a great example of federally funded research that needs to continue. So, great job by the study team. The DFS 10% difference is really very large and certainly a practice-changing study. Dr. Shaalan Beg: Yeah, and and sticking with colon cancer, and and this another federally funded study, but this time funded by a Canadian cancer clinical trials group was LBA3510. This is the CHALLENGE study. It's a randomized phase 3 trial of the impact of a structured exercise program on disease-free survival for stage III or high-risk stage II colon cancer. This study got a lot of buzz, a lot of mainstream press coverage, and a lot of discussions on what that means for us for the patients who we're going to be seeing next week in our clinic. What was your takeaway? Dr. Kristen Ciombor: Yeah, this is a really interesting study, and I was so glad to see it presented because this partially answers one of the questions that patients always have for us in clinic, right? You know, once they've completed their standard chemotherapy and surgery, what else can they do to help prevent recurrence? And so we've always known and sort of extrapolated that healthy lifestyle habits are good, but now we have data, particularly in these patients. Most of them were stage III colon cancer patients, those had high-risk stage II cancer. And basically, the goal was to increase their physical activity by at least 10 MET hours per week. So, my big question, of course, as I came into this presentation was, “Okay, what does that mean exactly? How does that translate to real life?” And really what the author presented and explained was that basically most patients could hit their target by adding a 45- to 60-minute brisk walk 3 to 4 times a week. So I think this is very approachable.  Now, in the confines of the study, this was a structured exercise program, so it wasn't just patients doing this on their own. But I do think kind of extrapolating from that, that this is very achievable for most patients. And not only did this prevent recurrence of their prior cancer, but actually the rate of new primary cancer diagnoses, was less, which is really interesting, especially in the breast and prostate cancer. So this was a really interesting, and I think practice-changing study as well, especially given that this is something that most patients can do. Dr. Shaalan Beg: Yeah, and there was a lot of discussion in the hallways after the presentation in terms of how this really changes our existing practice because most folks already recommend exercise as a way for improving outcomes in cancer patients. So we've already been doing that. Now we have some data on how much it can impact the benefit. But there was some discussion about what the actual degree of impact was. There was a drop-off rate in terms of how long folks were able to stick with this exercise regimen. But you've seen this in clinic when someone have their surgery, they have their chemotherapy, they've been so intimately involved with the oncology world, with the oncology practice, and they somehow feel that they're being let loose into this mean, angry world without any guidance and they're looking for something to do. “What more can I do in terms of my lifestyle?” And then here we have very solid data, as solid as can be for an intervention like exercise, showing that there is an impact and you can give a prescription for exercise when someone wraps up their chemotherapy for colon cancer, thanks to the study. Dr. Kristen Ciombor: Yeah. It was a great study. Dr. Shaalan Beg: Moving to gastroesophageal cancer, another late-breaking abstract. This is LBA5. The MATTERHORN trial was a phase 3 trial of durvalumab plus FLOT for resectable GE junction and gastric cancer. And again, another area where immunotherapy has made an impact, and here we're seeing it move closer for earlier-stage disease. What was your take-home for the MATTERHORN trial? Dr. Kristen Ciombor: Yeah, so this study looked at neoadjuvant perioperative durvalumab plus our current standard chemotherapy of FLOT versus placebo plus FLOT. And this was a large study, almost 1,000 patients were randomized. And the primary endpoint was event-free survival, and it was definitely met in favor of the D + FLOT arm, as Dr. Klempner discussed after Dr Janjigian's presentation. I do think there are still some unanswered questions here. Overall survival is not yet mature, so we do have to wait and see how that shakes out. But it's very interesting and kind of is reflective of what, as you said, we're looking at earlier and earlier lines of therapy, particularly with immunotherapy, in these GI cancer spaces. So it makes a lot of sense to test this and and to look at this. So the toxicity was pretty similar to what we would expect. Primary endpoint was met, but again, we'll have to wait and see what the survival data looks like. Dr. Shaalan Beg: Yeah, and in oncology, we know, especially for treatment that does add additional cost, it does add additional potential toxicity that we want to see that overall survival nudged. I did see some polls on social media asking folks whether their practices changed from this, and I think the results were favoring adding durvalumab for this group of patients but understanding that there are caveats to the addition of treatments and the eventual FDA approval in that indication as well. Dr. Kristen Ciombor: Exactly. I completely agree with that. Dr. Shaalan Beg: All right. How about we stick with gastroesophageal cancer? LBA4002 was trastuzumab deruxtecan versus ramucirumab plus paclitaxel for second-line treatment in HER2-positive unresectable or metastatic gastric cancer or GE junction cancer. This was the DESTINY-Gastric04 study. And again, antibody-drug conjugates making a big impact across different diseases. And here we have more data in the HER2-positive gastric cancer space. Your thoughts on this study? Dr. Kristen Ciombor: Yeah, so this is a really important space in gastroesophageal cancer because the HER2 positivity rate is fairly high as compared to some of our other tumor types. So, I do think one of the important things was that patients did have biopsy confirmation of HER2 status, which was very important, and then they were randomized to either T-DXd versus the kind of second-line standard of ramucirumab-paclitaxel. So this was a great practical study and really answers a question that we had for a while in terms of does anti-HER2 therapy in the second-line really impact and improve survival. So we did see a statistically significant improvement favoring T-DXd. I do think it's always important to look at toxicity, though, too. And there was about almost 14% rate of interstitial lung disease, which of course is the most feared toxicity from some of these antibody-drug conjugates, especially T-DXd. So I do think it's important to keep that in mind, but this is definitely a great addition to the armamentarium for these HER2-positive patients. Dr. Shaalan Beg: And pancreas cancer was on the stage after a very long time with a positive clinical trial. This is Abstract 4006. These were preliminary results from a phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone for previously untreated metastatic pancreas cancer. This is a frontline clinical trial of gemcitabine/nab-paclitaxel plus/minus the study drug. There were other cohorts in this study as well, but they reported the results of their part 3B arm. And great to see some activity in the pancreas space. And your thoughts? Dr. Kristen Ciombor: Yeah, we definitely need better treatments in pancreas cancer. This was a very welcome presentation to see. The elraglusib is an inhibitor of GSK-3beta, and it's thought that that mediates drug resistance and EMT. And so this is, I think, a perfect setting to test this drug. So patients basically were randomized. Patients with metastatic pancreas cancer were randomized 2: 1 to gemcitabine/nab-paclitaxel plus or minus this elraglusib. So, what we saw was that overall survival was better with the addition of this new drug. And overall, not only the 1-year overall survival, but also median overall survival.  The thing that was interesting, though, was that we saw that the overall survival rates were 9.3 months with the combination versus 7.2 months with just gemcitabine/nab-paclitaxel. And that's a little bit lower than we've seen in other studies. So, not sure what was going on there. Was it the patients that were a bit sicker? Was it a patient selection, you know, thing? I'm not really sure how to explain that so much. Also, the toxicity profile was much higher in terms of visual impairment, with over 60% of patients being treated with the combination versus 9% with gemcitabine/nab-paclitaxel. So these were mild, grade 1 and 2, but still something to be cautious about. Dr. Shaalan Beg: And especially with this being a phase 2 trial, making sure that in a larger study we're able to better evaluate the toxicity and see if the control arm in the larger confirmatory study performs differently will be really important before this compound makes it to the clinic in our space. But very exciting to see these kinds of results for pancreas adenocarcinoma. Dr. Kristen Ciombor: Yeah. Dr. Shaalan Beg: We've talked, it seems, a couple of times on this podcast about the BREAKWATER clinical trial. We did hear PFS and updated OS data, updated overall survival data on first-line encorafenib plus cetuximab plus modified FOLFOX6 for BRAF-mutated colorectal cancer. This was LBA3500. And eagerly anticipated results – we have all previously heard the progression-free survival results – but here we heard updated overall survival results, and very well-received study it seemed from the audience that time. So what are your takeaways on the updated results for BREAKWATER? Dr. Kristen Ciombor: In my opinion, this was one of the most practice-confirming studies. As you mentioned, we've already seen some of the preliminary data of BREAKWATER at prior meetings. But really what was particularly impactful for me was the median overall survival with the BREAKWATER regimen. So, again, patients received FOLFOX, encorafenib cetuximab in the first line if they had BRAF-mutated V600E-mutated colorectal cancer. And the median PFS was 12.8 months, which was actually really remarkable in this traditionally very aggressive, poor prognosis subtype of tumors. So, by seeing a median overall survival of 30.3 months was just incredible, in my opinion. Just a few years ago, that was considered the median overall survival for all comers for metastatic colorectal cancer. And we know the median overall survival was more in the less than 12 months range for BRAF. So this was incredibly impactful, and I think should be absolutely practice-changing for anyone who is eligible for this regimen.  I think again, where the practice meets the study is what's kind of important to think about too, how long did patients get FOLFOX, and certainly it adds toxicity to add a BRAF-targeted regimen on top of FOLFOX already. So, one of the other interesting things about the study, though, was that even though it didn't complete treatment, they actually did look at encorafenib/cetuximab alone and in the first line without chemotherapy. And those preliminary results actually looked okay, especially for patients who might not be able to tolerate chemotherapy, which we certainly see in practice. So, overall, definitely more data. And I agree that it's certainly practice-changing. Dr. Shaalan Beg: And it completely, as you mentioned, changes the outlook for a person who's diagnosed with BRAF-mutated metastatic colon cancer today versus even 7 or 8 years ago. Dr. Kristen Ciombor: And we're seeing this over and over in other subtypes too, but how you choose to treat the patient up front really matters. So really giving the right regimen up front is the key here. Dr. Shaalan Beg: And along the same lines, Abstract 3501 wanted to answer the question on whether people with MSI-high metastatic colorectal cancer need double checkpoint inhibitor therapy or is single therapy enough. So this [CheckMate-8HW] study compared nivo plus ipi with nivo alone, nivo monotherapy for MSI-high metastatic colorectal cancer. And we've known that both of these are fairly active regimens, but we also know the chance of immune-related adverse events is significantly higher with combination therapy. So this was a much-needed study for this group of patients. And what were your takeaways here? Dr. Kristen Ciombor: This, of course, has been really nivo-ipi in the first-line MSI-high metastatic colorectal cancer is now a standard of care. And not everybody is eligible for it, and there could be reasons, toxicity reasons, and other things too. But as we've been seeing for the last couple of years, immunotherapy clearly beats chemo in this space. And now looking at doublet versus single immunotherapy treatment in the first line, I think really nivo-ipi does beat out monotherapy. I will say, however, there is a caveat in that we still haven't seen the nivo-ipi versus nivo in the first line. So what has been presented thus far has been across all lines of therapy, and that does muddy the waters a little bit. So definitely looking forward and and we've asked this many times and based on the statistical plan and and what not, you know, we just haven't seen that data yet. But I do think it's becoming increasingly important to consider doublet immunotherapy for these patients as long as there are no contraindications. With the again, with the caveat that we have to have these toxicity discussions in the clinic with patients because many patients can tolerate it, you know, this regimen fairly well, but there can be very severe toxicities. So, I think an informed discussion should really be had with each patient before moving forward. Dr. Shaalan Beg: Yeah, informed decision, making them aware of the potential of real significant toxicities, immune-related toxicities with double therapy. But I am curious in your practice, how often do you see people choosing doublet therapy as frontline? Dr. Kristen Ciombor: So patients are really savvy, and a lot of times they've heard this data before or have come across it in patient advocacy groups and other things, and it's really nice to be able to have that conversation of the risk versus benefit. So I will say not all of my patients choose doublet, and many of them are still cured with immunotherapy monotherapy. So the big question there is, will we ever understand who actually needs the doublet versus who can still be cured or have very good long-term outcomes with just the single agent? And that has not been answered yet. Dr. Shaalan Beg: What a great point. So the last abstract I was hoping we could talk about is POD1UM-303 or the INTERAACT2 subgroup analysis and impact of delayed retifanlimab treatment for patients with squamous cell carcinoma of the anal canal. What were your thoughts here? Dr. Kristen Ciombor: This was a study, actually we saw at ESMO, we saw the primary data at ESMO last year, and this was an update with some exploratory analyses. But this was really an important study because once again, we're looking at immunotherapy in later lines of therapy. That's how we started looking at and investigating immunotherapy, and now we're moving it up and up in the treatment course. So this was a study of carboplatin/paclitaxel plus or minus retifanlimab. Actually it was retifanlimab versus placebo. And it was a positive study, as we heard last year. This actually led to FDA approval of this regimen last month, just before ASCO, and it has now been incorporated in the NCCN guidelines as the preferred first-line option.  So what I thought was important from the additional data presented at ASCO was looking at the different subgroups, it did not appear that patients with liver mets or not had different outcomes. So that was really good to see because sometimes in colon cancer we see that immunotherapy doesn't work as well when patients have liver mets. And interestingly, because we use immunotherapy in anal cancer without any biomarkers, unlike with colon cancer or some of the other tumor types, also the authors looked at PD-L1 status, and it did look like maybe patients did a little bit better if they had higher PD-L1 expression, but patients still could benefit even if they were PD-L1 negative. So that was important, I think, and we will continue to see further data come out from this study. I want to mention also that EA2176 just completed accrual, so that was carbo-taxol plus or minus nivolumab. And so we should be seeing that data sometime soon, which will hopefully also confirm the ongoing role for immunotherapy in the first-line setting for anal cancer. Dr. Shaalan Beg: That was a fantastic review. Thank you, Dr Ciombor. Thanks for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Kristen Ciombor: Thanks for having me here. Dr. Shaalan Beg: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Shaalan Beg  @ShaalanBeg  Dr. Kristen Ciombor @KristenCiombor Follow ASCO on social media:    @ASCO on Twitter   @ASCO on BlueSky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Shaalan Beg:   Consulting or Advisory Role: Ipsen, Cancer Commons, Foundation Medicine, Science37, Nant Health, Lindus Health Speakers' Bureau: Sirtex Research Funding (Inst.): Delfi Diagnostics, Universal Diagnostics, Freenome Dr. Kristen Ciombor: Consulting or Advisory Role: Pfizer, Incyte, Exelixis, Bayer, ALX Oncology, Tempus, Agenus, Taiho Oncology, Merck, BeiGene Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calthera, Genentech, Seagen, Syndax Travel, Accommodations, Expenses: Incyte, Tempus

Managing pain in pediatric patients is a critical aspect of prehospital care. Yet, this remains a challenging area for many EMS providers.   A new study out called “Barriers and Enablers in Prehospital Pediatric Analgesia” sheds light on the complexities of assessing and treating pain in children during ambulance rides. Led by Dr. Hoi See Tsao, Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center, the research identifies key hurdles EMS workers face and suggests actionable solutions to improve care.   Dr. Tsao, a specialist in pediatric emergency medicine with a passion for prehospital care, shared her insights and findings during a recent interview. “When pain in kids is not treated, it can lead to adverse effects such as increased anxiety, decreased pain tolerance, and fear of future healthcare encounters,” she pointed out. The stakes are high, and the study highlights both challenges and opportunities for EMS professionals.

In this specialty podcast, Dr. Alissar El Chediak is joined by Dr. Jon Odorico and Dr. Ron Parsons to discuss the current state of pancreas transplantation, identify barriers and strategies for referral and candidate selection, and discuss solutions to address the decline in procedures. Alissar El Chediak, MD is a transplant nephrologist at UT Southwestern Medical Center. Jon Odorico, MD is a transplant surgeon at the University of Wisconsin. Ron Parsons, MD is a transplant surgeon at the University of Pennsylvania.   References: Generating strategies for a national comeback in pancreas transplantation: A Delphi survey and US conference report

On Tuesday, Abundance Energy, sonnen and Energywell announced a collaboration meant to bring the behind-the-meter, battery-enabled technology to the Lone Star State. A virtual power plant is a network of decentralized energy sources working together to generate, store and manage electricity. In other news, a political action committee accused of breaking election laws raised six figures for a Prosper Independent School District trustee election — but its secretive spending failed to unseat the two incumbents it aimed to replace; Children's Health and UT Southwestern Medical Center announced on Tuesday that they have secured a nine-figure financial donation as they work toward constructing a $5 billion pediatric campus in Dallas that will span nearly 5 million square feet; and Micah Parsons wants a new contract with the Dallas Cowboys. A first-round draft pick in 2021, the premier edge rusher has become a household name as one of the most feared defenders in the NFL. Parsons, a four-time Pro Bowler who has twice been named to the All-Pro team, has 52.5 sacks in four seasons. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Hey y'all, this week, I'm so excited to introduce you to someone who's doing truly innovative work at the intersection of clinical care and coaching.Laura Kirk is the Assistant Director of Advanced Practice Providers at UT Southwestern Medical Center in Dallas, Texas, and she also serves as Vice President of External Education for the Academy of Communication in Healthcare (ACH). She's a Physician Assistant, a certified life coach, a leader, and a total force for humanistic change in the healthcare space.In this episode, Laura shares her personal evolution—from practicing PA to coaching advocate to system-level change agent. At UT Southwestern, she's part of a clinician coaching program designed to support well-being, enhance communication, and ultimately improve patient care.Laura talks about what it's like to see coaching integrated into the heart of a massive academic health system, and why it's worth investing in these skills—not just for personal growth, but for culture change in medicine.

Josh Blackwell, PharmD, MS, BCSCP, is the Co-Founder of Pharmacy Initiative Leaders (PILs) and is a Clinical Pharmacy Manager at UT Southwestern Medical Center. We talk through the power of mentorship and how PILs was designed to fill a gap in mentorship for pharmacy professionals. PILs has helped pharmacy leaders to be at their best for every stage of their career. He has great advice for new and seasoned practitioners on being both a mentee and a mentor! 

Mark Meyer (Chief Financial Officer Health System at UT Southwestern Medical Center) and Kelly Kloeckler (Associate Vice President Revenue Cycle Operations, UT Southwestern) Discuss the methods and tactics their team has found succes in at UT. This episode is brought to you by our good friends at Switch RCM. Please reach out to Nate and the team: Nate@switchrcm.com You will not regret it. Those cats are doing some very interesting things. Don't forget to like and subscribe!

Dr Thomas Hutson from UMC Cancer Center in Lubbock, Texas, Dr Rana McKay from UC San Diego Moores Cancer Center in California, Dr Tian Zhang from UT Southwestern Medical Center in Dallas, and moderator Dr Sumanta Kumar Pal from City of Hope Comprehensive Cancer Center in Duarte, California, discuss published data and updates from the 2025 ASCO Genitourinary Cancers Symposium meeting on management strategies for clear cell and non-clear cell renal cell carcinoma. CME information and select publications here.

Dr Thomas Hutson from UMC Cancer Center in Lubbock, Texas, Dr Rana McKay from UC San Diego Moores Cancer Center in California, Dr Tian Zhang from UT Southwestern Medical Center in Dallas, and moderator Dr Sumanta Kumar Pal from City of Hope Comprehensive Cancer Center in Duarte, California, discuss published data and updates from the 2025 ASCO Genitourinary Cancers Symposium meeting on management strategies for clear cell and non-clear cell renal cell carcinoma. CME information and select publications here.

“I think everyone should have Lp(a) measured.”  Dr. Ann Marie Navar    Key Resources to Go Deeper:  - Dr. Ann Marie Navar  - Lp(a)  - Get a Free Test to Check Your Lp(a) Level   - Previous episode with Dr. Navar about ApoB  About This Episode:  Join us for an enlightening discussion about Lipoprotein(a), or Lp(a), a critical but often overlooked marker for cardiovascular health. In this episode, host Barbara Hannah Grufferman takes a deep dive with medical expert Dr. Ann Marie Navar from UT Southwestern Medical Center about why this single test could be vital for understanding your heart disease risk, especially if you have a family history of early cardiovascular disease.  Key Topics Covered:  - What Lipoprotein(a) is and how it differs from standard cholesterol measurements  - Why Lp(a) testing is particularly important for certain individuals  - The genetic nature of Lp(a) and its implications for family health  - Current treatment options and promising new therapies on the horizon  - Practical steps for discussing Lp(a) testing with your healthcare provider  Key Takeaways:  - Lp(a) is a distinct type of cholesterol particle not captured in routine lipid panels  - High Lp(a) levels significantly increase risk of heart disease and stroke  - Lp(a) levels are primarily determined by genetics and remain stable throughout life  - Current guidelines recommend universal Lp(a) testing for adults  - New treatments specifically targeting high Lp(a) levels are expected by 2026  - Managing other risk factors can help offset the risk of elevated Lp(a)  - Coronary artery calcium scoring can provide additional risk assessment  Learn More About Dr. Ann Marie Navar  Dr. Navar is a preventive cardiologist and epidemiologist at UT Southwestern Medical Center whose research focuses on cardiovascular disease prevention, risk prediction, and clinical decision-making. She is a leading expert in advanced lipid testing and cardiovascular risk assessment. This is Dr. Navar's second appearance on AGE BETTER, following her previous discussion about the ApoB test, which was one of the most down-loaded episodes in 2024.   Connect With Barbara:  Have ideas for future episodes? We'd love to hear from you!  - Email: agebetterpodcast@gmail.com  - Connect on Instagram HERE  Note: This episode is for informational purposes only and does not constitute medical advice. Please consult with your healthcare provider about your specific situation.  Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Brain & Life Podcast, co-host Dr. Katy Peters is joined by Shea Hammond, athlete and founder of CP Soccer. Shea shares about his personal experience growing up with Cerebral Palsy (CP) and how staying active and working with a physical therapist has helped him continue to reach his goals. He also discusses CP Soccer's mission, to build a nationwide soccer league for kids who are affected by cerebral palsy, stroke or traumatic brain injury, and what's next for the organization. Dr. Peters is then joined by Dr. Mauricio Delgado, professor of neurology at UT Southwestern Medical Center, former president of the American Academy for Cerebral Palsy and Developmental Medicine and co-founder member of the Mexican Academy for Cerebral Palsy and Neurodevelopmental Disabilities. Dr. Delgado explains how CP is diagnosed and treated, and what the future for those affected and their caregivers looks like.   Additional Resources CP Soccer Biking Gives Freedom to a Teen with Cerebral Palsy How Parents Advocate for Their Children with Rare Diseases   Other Brain & Life Podcast Episodes RJ Mitte on Living Confidently with Cerebral Palsy Gavin McHugh is Building an Acting Career and a Community with Cerebral Palsy Josh Blue Uses Humor to Ease the Stigma Around Cerebral Palsy We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? ·       Record a voicemail at 612-928-6206 ·       Email us at BLpodcast@brainandlife.org   Social Media: Shea Hammond @shea_hammond; Dr. Mauricio Delgado @utswmedcenter Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Heather McArthur, Associate Professor in the Department of Medicine at University of Texas, UT Southwestern Medical Center, USA. They discuss recent advancements in breast cancer immunotherapy and the future of personalised care.  Timestamps:    00:00 - Introduction  01:20 - Transformative breakthroughs in immunotherapy  03:51 - Communicating new research to the public  05:48 - Racial disparities in cancer screenings  07:22 - Unmet needs in treating triple-negative breast cancer  11:48 - Genomic profiling and molecular pathways   13:30 - Barriers to personalised treatment plans  15:09 - Designing and conducting large-scale, international trials  19:16 - Optoacoustic imaging in cancer  22:52 - The ‘first' cell and the heterogeneity of breast tumours  25:21 – Heather's three wishes for healthcare 

Richard Winters, M.D. is an emergency physician at Mayo Clinic in Rochester, Minnesota. He is the director of leadership development for the Mayo Clinic Care Network, a member network of over 47 national and international healthcare systems. Dr. Winters develops and delivers leadership programs and provides executive coaching for leaders around the world. Dr. Winters authored the Wall Street Journal bestselling book You're the Leader. Now What?: Leadership Lessons from Mayo Clinic, which was published by Mayo Clinic Press on September 6, 2022. And he serves as core faculty for the Accelerate Leadership Program at Mayo Clinic.Dr. Winters is a consultant in Emergency Medicine and finance chair for the Midwest Department of Emergency Medicine at Mayo Clinic in Rochester, MN. He serves on the Rochester Emergency Department Executive Committee and the Specialty Council for Emergency Medicine.Prior to returning to Mayo Clinic in March of 2015, Richard served as the President of an 800-physician medical staff, President/CEO of an Independent Practice Association in the Central Valley of California with 450-physician members, as CEO of a Physician Hospital Organization, and as Managing Partner of a democratic emergency medicine partnership.He is a graduate of the University of Texas at Dallas Executive and Professional Coaching Program and is an International Coaching Federation professional certified coach. Richard completed a Healthcare Management Executive MBA from the University of Texas at Dallas and UT Southwestern Medical Center. He obtained a Bachelor of Science in Biological Sciences from the University of Illinois at Chicago. Dr. Winters attended Mayo Medical School from 1990-1994. He is board certified and residency trained in Emergency Medicine from the University of California, San Francisco at Fresno.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

Dr. Shaalan Beg and Dr. David Wang discuss key abstracts in GI cancers from the 2025 ASCO Gastrointestinal Cancers Symposium, including major advances in CRC, neoadjuvant approaches in esophageal cancer, and innovative studies on ctDNA. TRANSCRIPT Dr. Shaalan Beg: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Shaalan Beg. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas. Today, we're bringing you some key highlights from the 2025 ASCO Gastrointestinal Cancers Symposium, and I'm delighted to be joined by the chair of GI25, Dr. David Wang. Dr. Wang is a GI medical oncologist at the University of Michigan. Our full disclosures are available in the transcript of this episode.  Dr. Wang, thanks for coming on the podcast today. Dr. David Wang: Well, thank you. It's a pleasure to be here. Dr. Shaalan Beg: GI25 featured major therapeutic advances across the spectrum of GI malignancies, and it was exciting to hear about innovations and novel approaches that are shaping the future of our field. Before we start talking about specific abstracts, could you share some of your key highlights from the meeting? Dr. David Wang: Sure. Our theme this year was “Breaking Boundaries to Enhance Patient Centered Care.” Past years' themes have focused more on precision oncology, but we wanted to broaden our focus on patients and to be more holistic, which kind of led us into some of the Intersection [sessions] that we had. Each day started with a different Intersection. The first one was “Emerging Therapies in GI Cancers”, where invited speakers talked about bispecific antibody drug conjugates, theranostics, CAR T and other cell-based therapies. The second day was on “Personalized Risk Assessment for GI Cancers,” and this included looking at polygenic risk scores for colorectal cancer, microRNAs and liquid biopsies such as exosomes and pancreatic cancer and non-endoscopic screening modalities in esophageal cancer. And on our final day, we wanted to talk about “Integrative Oncology and Integrative Medicine,” looking at evidence-based uses of acupuncture and supplements in patients who are receiving treatment for cancer, mindfulness-based practices and exercise. And of course, we had a fantastic keynote talk by Dr. Pamela Kunz from the Yale School of Medicine titled, “Disrupting Gastrointestinal Oncology: Shattering Barriers with Inclusive Science.” She highlighted the intersection of science, patient care, and health and gender equity. And I would encourage your podcast listeners to access the lecture in ASCO's Meeting Library if they haven't yet had a chance to hear Dr. Kunz's wonderful lecture.  We were really happy this year because the attendance hit a new record. We had over 5,000 people attend either in person or virtually from their home or office, and we had almost 1,000 abstracts submitted to the meeting, so these were either record or near record numbers. We offered a lot of different networking opportunities throughout the meeting, and attending found these to be incredibly rewarding and important and this will continue to be an area of emphasis in future meetings. Dr. Shaalan Beg: Let's take a deeper dive into the exciting studies presented at GI25. The late breaking abstract LBA143 was CheckMate-8HW. This was the first results of NIVO + IPI versus NIVO monotherapy for MSI-high metastatic colorectal cancer. What are your thoughts about this study? Dr. David Wang: Yeah, so we know that colorectal cancer patients with MSI-high tumors don't necessarily respond well to chemotherapy. And we were fortunate because last year CheckMate-8HW actually looked at two different arms – so this was NIVO + IPI compared to standard of care chemotherapy and showed its very significant improvement in median progression-free survival. And that was actually published in the New England Journal of Medicine back in November of 2024. This year's presentation actually focused now on NIVO + IPI versus NIVO monotherapy. And as you know IPI+NIVO can be quite toxic. So this was an important analysis to be done. So we know that NIVO is definitely more easily tolerated. So what was interesting was that the 2-year and 3-year progression-free survival not surprisingly favored IPI+NIVO and this was statistically significant. And the overall response rate was also better with IPI+NIVO versus NIVO alone. I know we're always concerned about toxicities and there were higher grade 3 and 4 toxicity incidences in the combination arm versus the monotherapy arm, but overall, only about 28 additional events in several hundred patients treated. So I think that's well-tolerated. Our discussant Dr. Wells Messersmith actually said that, with this new data, he would consider doing combination immunotherapy in any patient that presented in the front line with MSI-high or deficient mismatch repair colorectal cancer that was metastatic. Dr. Shaalan Beg: One of the focuses for directing first-line therapy for colorectal cancer has been right and left sided colon cancer because we know these are two different cancers with their own unique molecular subtypes. We heard on Abstract 17, the DEEPER trial, the final analysis of modified FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left sided metastatic colorectal cancer. How do you summarize the findings of this study and what should our readers be aware of? Dr. David Wang: Interestingly, this was a phase 2 study and the emphasis of the abstract was actually a subgroup analysis of those patients with RAS wild-type and BRAF wild-type as well as left sided cancers. So, I think the entire study enrolled 359 patients, but the analysis that was discussed at the meeting really focused on 178 patients that fit that characteristic. Very similar to what we've seen in prior studies, left-sided tumors have better response to cetuximab versus bevacizumab. And if you flip it so that you now are looking at right sided tumors, targeting EGFR is actually detrimental. The depth of response was better with cetuximab in these left sided RAS and BRAF mutant tumors. And so the lead author actually suggested that this could be a new first-line standard of care. And the question is, is there a benefit of doing this triple agent regimen with modified FOLFIRINOX? We know there's a lot more toxicity with that. Not clear that there's a benefit for that over FOLFOX, maybe in younger patients that could tolerate it. When our discussant, again Dr. Wells Messersmith, spoke about this, he said that, in his practice he would, again, favor cetuximab over bevacizumab in combination with chemo, these left-sided RAS and BRAF wild-type tumors, but that he would actually prefer a doublet versus a triplet chemo regimen, and that is consistent with the current NCCN guidelines. Dr. Shaalan Beg: Another area where colorectal cancer has been a wonderful model to study new technology has been in the area of circulating tumor DNA (ctDNA). And the BESPOKE CRC trial is looking to see if ctDNA can inform adjuvant treatment decisions for stage II and III colorectal cancer. And in Abstract 15, we heard final results of the BESPOKE CRC sub-cohort. What were the findings there? Dr. David Wang: BESPOKE CRC is another one of these important ctDNA studies. It was an observational study, not a randomized trial, but it did provide a lot of different insights to us. We know that there were over 1,700 patients enrolled, and so it was reported that this is the largest ctDNA study in colorectal cancer performed in the United States. And they were able to analyze over 1,100 patients.  Some of the key findings were that postoperative adjuvant therapy management decisions actually changed in 1 out of 6 patients, so that's pretty significant. In terms of surveillance, we know that patients who have ctDNA positivity, this is prognostic of recurrence. In terms of patients who have positive ctDNA post-surgery, it looked like, at least in this observational study, the majority of patients who received any benefit were those who had positive ctDNA. So adjuvant therapy, even in stage II and stage III patients seemed to only benefit those patients who have positive ctDNA. I think that does raise the question, and this also was brought up in the discussion, which is “Can we de-escalate adjuvant therapy in terms of patients who are ctDNA-negative post-op?” And Dr. Richard Kim from Moffitt felt that we are not yet there. Obviously, we need randomized control trials where we are taking ctDNA results and then randomizing patients to receive adjuvant or non-adjuvant to really know the difference.  Other questions that come up with use of ctDNA include: What do you do with these patients who turn positive? This study for BESPOKE actually followed patients out to two years after surgery. So what you do with a positive ctDNA result wasn't really clear. It seems to suggest that once you turn positive, patients go on to more intensive surveillance. You know, again as an observation, patients who did turn positive were able to go to metastasis-directed therapy much more quickly. And again, this was supposedly to improve their curative intent therapy. And I think the other question that has been brought up all the time is, is this really cost effective? Patients want to know, and we want to give patients that information, but I think we're still stuck with what to do with a positive ctDNA level in a patient that's on surveillance because no randomized control studies have actually suggested that we need to start systemic therapy right away. Dr. Shaalan Beg: Yeah. And I guess in terms of practice informing or practice changing, these results may not give us a clear answer. But because a lot of patients are asking for these tests, it does give us some real world experiences on what to expect in terms of conversion of these positive into negative and the outcome so we can have a shared decision making with our patients in the clinic and then come up with a determination on whether ctDNA for molecular residual disease is something which would be worthwhile for the care of our patient. But more to come, I guess, in coming years to answer different problems around this challenge. Dr. David Wang: Yes, I agree. Dr. Shaalan Beg: The BREAKWATER trial looked at the use of encorafenib, cetuximab and chemotherapy for BRAF V600E-mutant metastatic colorectal cancer. We've covered this combination for a second- third-line treatment in metastatic colorectal cancer previously. Abstract 16 from GI25 was evaluating the use of this regimen in the first-line space. Everyone was looking forward to these results, and what did the investigators present? Dr. David Wang: I think this is, as you mentioned, a nice follow up to later lines of therapy where Dr. Kopetz from MD Anderson pioneered use of encorafenib, cetuximab and binimetinib in the BEACON trial. Everybody was kind of curious what would happen now if you use encorafenib plus cetuximab plus chemotherapy in the first-line setting. And so this is an interim analysis that was pre-planned in the phase 3 open label BREAKWATER trial. And even though there were three arms, and so the three arms were encorafenib plus cetuximab, encorafenib plus cetuximab plus FOLFOX, or standard of care chemo, only two arms were presented in the abstract. So basically looking at encorafenib plus cetuximab and FOLFOX-6 versus standard of care therapy, and the overall response rate was statistically significant with a 60.9% overall response rate encorafenib plus cetuximab plus chemo arm versus standard of care chemo was only 40%. The interim overall survival also was different. It was 92% versus 87% at 6 months and 79% versus 66% at 12 months, again favoring the chemotherapy plus encorafenib plus cetuximab. In terms of the statistics, the p was 0.0004. However, the pre-plan analysis required the p-value to be 1x10 to the -8. And so even though this looks really good, it hasn't quite met its pre-specified significance level. The good thing is that this is only interim analysis and the study is ongoing with future analysis planned.  So the real question is: Does it matter when we actually use this regimen? We know that the regimen's approved in the second third-line setting. What about in the first line? And there was some preclinical data that the discussant reviewed that shows that patients actually benefit if this is done in the first-line setting. For example, there was some preclinical data showing that even FOLFIRI, for example, can upregulate RAS, which would make tumors more resistant to this combination. This was thought to be practice-changing in a patient that has B600E showing up treatment naive that we should probably consider this regimen. And actually this did receive accelerated FDA approval about a month ago. Dr. Shaalan Beg: Yeah, and for what it's worth, I put up a Twitter poll asking my Twitter followers on how the BREAKWATER trial results will change their approach for newly diagnosed BRAF mutated colorectal cancer. We got 112 responses; 72% said that they will incorporate encorafenib, cetuximab, FOLFOX for their frontline BRAF mutated patients. But 23% said that they would like to wait for overall survival results. Dr. David Wang: Wow, that's interesting. They really want that 1x10 to the -8. Dr. Shaalan Beg: I guess so. All right. Let's change gears and talk about esophageal cancer. LBA329 was the SCIENCE study which presented preliminary results from a randomized phase 3 trial comparing sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant resectable locally advanced squamous esophageal cancer. Where are we in this space? Dr. David Wang: Okay. So, yeah, this was an interesting trial. Again, just to set the context, esophageal squamous cell carcinoma is more prevalent in Asia. And the study sites as well as the patients were mostly from Asia. So this was again a phase 3 trial with interim results. They only rolled 146 out of the planned 420 for this interim analysis. And yeah, they're using immune checkpoint inhibitor that we don't use in the United States, sintilimab, combined with their two standards of neoadjuvant therapy, either chemotherapy, which is more common in Asia, or or chemoradiation, which is more common in the US and Western Europe, versus chemoradiation. And so they actually had two primary endpoints, but only were reporting one. So their two primary endpoints were pathCR and the other one was event-free survival. The event-free survival, again, was not reported at the meeting.  What they found was that in terms of pathCR rate, if you take the two arms that are really informative about that, chemoradiation plus sintilimab versus chemoradiation alone, the pathCR rate was 60% versus 47%. We know that chemo alone doesn't induce as much of a pathCR rate, and that was 13%. So it was found that the delta in terms of pathCR between the chemoradiation arms, one with sintilimab and one without, was significant. And this actually confirms data again from Asia, like for the ESCORT-NEO trial where it used another immune checkpoint inhibitor pembrolizumab in addition to neoadjuvant chemo.  So as our discussant for this abstract said, yes, we know that radiation combined with chemotherapy improves pathCR rates, but we have recent data from the ESOPEC trial, we don't know that that necessarily will translate to overall survival. So again, waiting for additional enrollments and longer term follow up before incorporating this into clinical care here. Dr. Shaalan Beg: So David, how do the results of the SCIENCE trial compare with our practice in the United States and ongoing studies asking questions for neoadjuvant therapy for esophageal carcinoma in the United States? Dr. David Wang: I think obviously immune checkpoint inhibitor in the new adjuvant setting is important. Jennifer Eads at UPenn is running that EA2174 which is looking at chemoradiation plus or minus nivolumab, and then in non-pathCR responders randomized to adjuvant nivolumab per CheckMate 577 or nivolumab with intensification adding ipilimumab. We know that the ESOPEC trial just came out, and was published actually during the meeting, and that really focuses on adenocarcinomas. So adenocarcinomas of the GE junction, distal esophagus, now, we would probably treat very similarly to gastric using perioperative FLOT. However, the standard in the US for esophageal squamous cell carcinoma remains neoadjuvant chemoradiation. We know that squamous cell carcinomas are more exquisitely sensitive to radiotherapy. And then obviously in those patients who don't achieve a pathologic complete response, the expectation would be that they would go on to receive nivolumab per CheckMate 577. Again, the thought is that these tumors are more sensitive to immunotherapy given their higher incidences of mutational changes. And so again, this kind of goes along with the positive results seen in the SCIENCE trial that we just discussed with sintilimab but also EFFECT-neo with pembrolizumab. Obviously, we await the results of Jennifer's trial. Dr. Shaalan Beg: And the last abstract I was hoping we could get your perspective on was Abstract 652, which is a Phase 3 study of everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumors, the STARTER-NET trial. What were the results of this study? Dr. David Wang: So, I just want to give a shout out because we did have a session at this year's GI ASCO that looked at more rare tumors. So appendiceal tumors, neuroendocrine tumors, those kinds of things. So again, I would encourage your listeners to listen to that session if they have interest in that. Another type of rare tumor was adenosquamous tumors.  But in terms of the STARTER-NET trial, this was again an interim analysis of his phase 3trial and it was looking at combining everolimus plus lanreotide versus everolimus. So we know that in pancreatic-gastric neuroendocrine tumors, if you have low Ki-67, a well differentiated tumor, that the standard of care really is a somatostatin analog, and sometimes if they're more aggressive, we kind of consider molecular targeted therapy with everolimus. This was asking the question of whether we should do the combination on the frontline. And what was interesting is in this study, the patients were actually more of a poor prognostic set. So they had Ki-67 up to 20% or these were patients that actually had multiple liver lesions. And what they found was a median for progression free survival was improved with a combination out to 29.7 months versus 11.5 months with the somatostatin analog alone, and that the overall response rate was 23% versus 8.3%, again, favoring the combination. If you looked at subgroup analysis, it was actually those patients who had Ki-67 greater than 10%, so the more aggressive tumors, or those with diffuse liver lesions that had the most benefit. So I think that would be the patient population I would consider this new combination with using would be those patients again with poorer prognosis neuroendocrine tumor phenotype. Dr. Shaalan Beg: Thank you very much, Dr. Wang, for sharing your insights with us today and your great work to build a robust GI Cancers Symposium this year. Dr. David Wang: Well, thank you. I mean that really is a cooperative effort. We appreciate all the members of the GI25 Program Committee as well as the ASCO staff that just made it an outstanding meeting. Dr. Shaalan Beg: And thank you to all our listeners for your time today. You'll find links to the abstracts discussed today on the transcript of this episode.  Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. Shaalan Beg @ShaalanBeg  Dr. David Wang Follow ASCO on social media:   @ASCO on Twitter  @ASCO on BlueSky ASCO on Facebook   ASCO on LinkedIn   Disclosures:  Dr. Shaalan Beg:  Employment: Science 37  Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine  Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals  Dr. David Wang: Honoraria:  Novartis Consulting or Advisory Role: Novartis, Cardinal Health, Bristol-Myers Squibb, BeiGene, Eisai  

In this episode, host Dan Karnuta welcomes Don Taylor, the chairman of the board of directors at the Healthcare Standards Institute Foundation, which is responsible for developing a national standard for the implementation of artificial intelligence as it relates to the governance of the healthcare industry. The in-depth discussion by the two faculty members and healthcare administration experts in The University of Texas at Dallas focuses on how artificial intelligence is being integrated into the healthcare industry and the urgent need for its governance and standardization. Since the use of AI is now, or soon will be, used in everything including clinical decision-making, administrative tasks, patient interaction and even insurance claims, Karnuta and Taylor discuss the significant concerns raised by its use including its ethics, patient privacy and organizational accountability. Karnuta is an associate professor in the Jindal School's Organizations, Strategy and International Management Area as well as director of its Professional Program in Healthcare Management. Taylor is a professor of practice in the Jindal School's Executive Education Area and director of its Alliance for Physician Leadership program. He also serves in the faculty of UT Southwestern Medical Center.

The cholesterol conundrum: Nutritionist Leyla Muedin discusses recent research suggesting that HDL, or 'good' cholesterol, may protect against brain atrophy and dementia. The study from UT Southwestern Medical Center, published in the Journal of Clinical Medicine, found that higher concentrations of small particle HDL are linked to better cognitive function and greater gray matter volume. Leyla emphasizes the importance of understanding cholesterol's role beyond just heart health and challenges common misconceptions. She also highlights the benefits of dietary fats and criticizes outdated medical advice that promotes low-fat diets. This episode encourages a more nuanced view of cholesterol and its significant impact on overall health.

TopMedTalk is at The American Society of Anesthesiologists (ASA)'s annual general meeting; Anesthesiology 2024. Here we discuss key anesthesia updates, emphasizing patient safety and comfort. Does the evidence support allowing clear liquids up to surgery to reduce thirst without raising risks? Do new challenges around GLP-1 drugs, which delay stomach emptying, call for tailored pre-op guidance? Also, should we be rethinking gabapentinoids, which recent studies show may not effectively reduce opioid use as once believed? Presented by Desiree Chappell, Monty Mythen and Mike Grocott with their guests, Girish P. Joshi, Professor, Anesthesiology and Pain Management at UT Southwestern Medical Center and Ben Gibbison, Associate Professor of Cardiac Anaesthesia and Intensive Care at the University of Bristol, Honorary Consultant at University Hospitals Bristol and Weston NHS Foundation Trust.

This week on the AHRMM Subject Matter Expert Podcast, recorded live at the AHRMM24 Conference, host Justin Poulin is joined by Tim Martin, Director of Purchasing at UT Southwestern Medical Center. Fresh off his team's recognition with the prestigious Heartbeat of Healthcare award, Tim opens up about his passion for professional development and nurturing future supply chain talent. He also dishes on the most unexpected item he's ever had to source and entertains the thought of time-traveling back to mentor his younger self. You won't want to miss out on this insightful and candid conversation! #PowerSupply #AHRMM #Podcast #HealthcareSupplyChain #HeartbeatOfHealthcare #ProfessionalDevelopment #Mentoring

In this compelling episode of The Life of Flow Podcast, host Miguel is joined by Shon Chakrabarti MD MPH, CMO of Limflow, Michael Siah, Director of Limb Salvage at UT Southwestern Medical Center, and Lucas. Together, they explore the groundbreaking acquisition of Limflow by Inari and its potential to revolutionize the treatment landscape for CLTI patients. Through dynamic discussion and candid reflections, the group unpacks the clinical, technical, and business implications of this strategic merger, highlighting its impact on patient outcomes, institutional approaches, and the future of endovascular therapies.Key Topics Covered:Understanding the Inari-Limflow Synergy (00:01 - 09:52):Why the acquisition makes sense for unmet patient needs.Strategic alignment with Inari's ethos of purpose-built solutions.Overlaps in vascular innovations and CLTI management.Clinical and Economic Implications of CLTI Therapies (09:53 - 24:04):The importance of vertical integration in hospitals for CLTI programs.Addressing misconceptions about the costs and outcomes of amputations.New reimbursement codes and economic incentives for hospitals.Evolution of DBA Techniques (24:05 - 38:43):The journey of deep vein arterialization from experimental to commercial viability.Insights into procedural advancements, including new access points and technologies.The collaborative WhatsApp group fostering a global exchange of ideas.The Path Forward: Research, Collaboration, and Education (38:44 - 48:24):The role of continued peer-to-peer training and global education in scaling CLTI solutions.Investigator-Initiated Research Programs to address pressing clinical questions.Future product developments and their potential to expand patient reach.What Lies Ahead for CLTI Therapies (48:25 - End):Predicting the evolution of the field over the next 5-10 years.Controversial yet thought-provoking ideas about preemptive applications of DBA.Reflections on patient outcomes and the transformative impact of new therapies.Memorable Quotes:“Inari and Limflow are united by a commitment to tackling large unmet patient needs with purpose-built solutions.” – Shon Chakrabarti“Even when DBA patency declines, patients often end up better off than when they started—this is a game changer.” – MiguelConnect with Us:Miguel – https://www.linkedin.com/in/miguel-montero-baker-a44354214/Lucas – https://www.linkedin.com/in/lucasferrermdGuests:Shon Chakrabarti – https://www.linkedin.com/in/shon-chakrabarti-md-mph-018a7394/Michael Siah – https://www.linkedin.com/in/michael-siah-965585b1/Stay tuned for future episodes diving deeper into groundbreaking innovations in cardiovascular and endovascular medicine. Don't forget to subscribe, leave a review, and share this episode with colleagues passionate about transforming patient care!

Dr. Sandra Hassink is joined by Dr. Ryan Buchholz, a Primary Care Pediatrician and Chief Medical and Quality Officer at a Community Health Center in Washington DC, as well as the Moderator and Abstract Chair for the Innovations in Obesity Prevention, Assessment, and Treatment Forum (IOPAT). Dr. Hassink is also joined by Dr. Sarah Barlow, Professor of Pediatrics at UT Southwestern Medical Center in Dallas, Texas and Program Chair for the SOOb H-Program. Together they unpack the 2024 AAP National Conference and Exhibition (NCE). Related Resources: • AAP National Conference and Exhibition, Website (https://aapexperience.org/) • AAP Section on Obesity (https://tinyurl.com/3rx2rm4r) • 2024 Section on Obesity Annual Course (https://tinyurl.com/2tuz5f74) • Institute for Healthy Childhood Weight, Website (https://tinyurl.com/yc88y53j)

In this episode of the Brain & Life podcast, co-host Dr. Katy Peters is joined by Christina Coates, president and founding member of an organization called Hypertrophic Olivary Degeneration Association (HODA). Christina shares about her own journey with hypertrophic olivary degeneration and how she was inspired to found HODA and build an advocacy community. Dr. Peters is then joined by Dr. Vikram Shakkottai, professor of neurology at UT Southwestern Medical Center in Dallas, Texas and Dedman Family Distinguished Chair in Neurologic Disease. Dr. Shakkottai discusses cerebellar ataxia, hypertrophic olivary degeneration, how these disorders are treated, and what upcoming research there is to look forward to.   We invite you to participate in our listener survey! By participating in the brief survey, you will have the opportunity to enter your name and email address for a chance to win one of five $100 Amazon gift cards.   Additional Resources HODA - Working to make HOD History Forming a Foundation Bolsters Hope After a Rare Diagnosis Advice for Caregivers of People with Rare Diseases What is ataxia and cerebellar or spinocerebellar degeneration?   Other Brain & Life Episodes on this Topic Neurofibromatosis Advocacy and Community Building with the Gilbert Family Foundation Making a Lasting Impact with The Brain Donor Project's Tish Hevel We Are Brave Together with Jessica Patay Strength in Unity: Advocating and Advancing Research for Brain Tumors   We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? ·       Record a voicemail at 612-928-6206 ·       Email us at BLpodcast@brainandlife.org   Social Media:   Guests: Christina Coates @hodassoc; Dr. Vikram Shakkottai @utswmedcenter Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD  

BigTentUSA, in partnership with Katie Couric Media, Majic Ink Productions, Level Forward and All*In Action Fund, hosted a panel discussion about the Oscar-nominated short film RED, WHITE AND BLUE. The short film centers on a single mother living paycheck to paycheck in Arkansas who is forced to cross state lines in search of an abortion. As Lorraine Bracco has said about the film, it's “23 minutes you'll never forget.”We were thrilled to welcome back award-winning journalist Katie Couric, who moderated this critical conversation featuring Oscar-nominated filmmaker and writer, director and producer of the film, Nazrin Choudhury, OBGYN and reproductive rights activist Dr. Austin Dennard, and Nourbese Flint, President of All*In Action Fund. The powerful discussion focused how abortion policy is creating a healthcare crisis for many women and how reproductive rights are impacting political messaging and voter turnout.Below are links to the video recording and the audio podcast of our panel discussion. Hope to see you at our upcoming speaker events!Please note a one-time link to watch the film before the panel discussion was generously provided by Majic Ink Productions. Please check the film website for the latest screening information and how you can watch the film. ABOUT OUR SPEAKERSNAZRIN CHOUDHURY is a UK-US filmmaker who left the pursuit of medicine and a brief career in politics after her first foray into screenwriting garnered her a Focus on Talent Award with DNA FILMS. She is the recipient of the Imison award for her critically-acclaimed play, MIXED BLOOD, and an Arts Council of England award for her novel-in-progress, MY ENGLAND. Based in Los Angeles, Nazrin works extensively across film and television as a writer/producer/showrunner. Nazrin's directorial debut on the short film, RED, WHITE AND BLUE - which she also wrote and produced - earned her an Oscar nomination in the Best Live Action Short Film category at the 96th Academy Awards.AUSTIN DENNARD, M.D. is an OBGYN from Dallas, Texas. Dr. Dennard had to leave Texas to receive abortion care after learning she was carrying a fetus with anencephaly, a fatal condition in which the skull and brain do not fully develop. Dr. Dennard began her medical career in The University of Texas Southwestern Health system working at Parkland Hospital in Dallas. In addition to being a clinician, she has served as a clinical professor at UT Southwestern Medical Center. Listen to Dr. Dennard's NPR Story here.NOURBESE FLINT is President of All*In Action Fund, working to achieve abortion justice and build the political power of voters of color.  Prior to coming to All*In Action Fund she was the Senior Director of Black Engagement at Planned Parenthood Federation of America, where she worked on the strategic partnership to strengthen Planned Parenthood's relationships within existing racial justice, reproductive justice, Black serving and civil rights organizations. Nourbese is a founding member of Trust Black Women, a national coalition dedicated to increasing respect and support of Black Women, and is one of the founding members of the Black Women's Democratic Club. She has been featured in MSNBC, CalMatters, Newsweek, and more.  MODERATORKATIE COURIC is an award-winning journalist and #1 New York Times best-selling author. Couric was the first woman to solo anchor a network evening newscast, serving as anchor and managing editor of the CBS Evening News from 2006 to 2011 following 15 years as co-anchor of NBC's Today show. In 2017, she founded Katie Couric Media (KCM), which has developed a number of media projects, including a daily newsletter, “Wake-Up Call”, a podcast, “Next Question”, digital video series and several documentaries. You can find it all at katiecouric.com.YOUTUBE RECORDING HEREAnd then Go… This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit bigtentnews.substack.com

Contrary to popular belief, you don't need decades of experience to master orthognathic surgery planning. With advancements in virtual surgical planning (VSP) and streamlined treatment approaches, even early-career surgeons can achieve precise, efficient results! Today, we are joined by Dr. Patrick Wong, Assistant Professor in the Department of Surgery at UT Southwestern Medical Center and an OMS specializing in orthognathic surgery, facial trauma surgery, and cleft and craniofacial surgery. In this episode, Dr. Wong shares insights into his simplified orthognathic treatment planning technique for residents, detailing the step-by-step process for executing these complex surgeries. He explains why the Steiner method for cephalometric analysis may fall short in modern practice and highlights his preferred facial projection reference methods for optimal outcomes. We also explore four critical factors to consider when rotating the maxillofacial complex, emphasize the importance of ethnic-specific planning in contemporary procedures, and hear practical advice for preparing for VSP. Additionally, Dr. Wong walks us through his own VSP sequence and wraps up with his favorite books, shows, tools, and more!Key Points From This Episode:A brief overview of Dr. Wong's training and his current practice setup.Insight into his simplified orthognathic treatment planning technique for residents.The step-by-step process for planning and executing orthognathic surgeries.Why the Steiner method for cephalometric analysis falls short in modern practice.Dr. Wong's preferred facial projection reference methods for optimal outcomes.Four factors to consider when rotating the maxillofacial complex.The emphasis on ethnic-specific planning in contemporary orthognathic procedures.How to use the 90-90-10-10 rule to achieve the best aesthetic results.Advice to help residents prepare for virtual surgical planning (VSP).Benefits of VSP for planning complex surgical procedures.A look at Dr. Wong's VSP sequence, from bite planning to soft tissue overlay.Recommended books, shows, non-OMS habits, and more in the rapid-fire section!Links Mentioned in Today's Episode:Dr. Patrick Wong on LinkedIn — https://www.linkedin.com/in/patrick-wong-29ab14239/Dr. Patrick Wong on Instagram — https://www.instagram.com/dr.patrickewong/Dr. Patrick Wong Email — patrick.wong@utsouthwestern.eduUT Southwestern Medical Center — https://utswmed.org/‘Barcelona line. A multicentre validation study of a facial projection reference in orthognathic surgery' — https://pubmed.ncbi.nlm.nih.gov/36609073/Can't Hurt Me — https://www.amazon.com/dp/1544512287Ego is the Enemy — https://www.amazon.com/dp/1781257027/True Detective — https://www.hbo.com/true-detectiveEveryday Oral Surgery Website — https://www.everydayoralsurgery.com/ Everyday Oral Surgery on Instagram — https://www.instagram.com/everydayoralsurgery/ Everyday Oral Surgery on Facebook — https://www.facebook.com/EverydayOralSurgery/Dr. Grant Stucki Email — grantstucki@gmail.comDr. Grant Stucki Phone — 720-44

In this episode of SEE HEAR FEEL, host Christine speaks with Dr. Yemi Sokumbi, a dermatologist and dermatopathologist at Mayo Clinic in Jacksonville, Florida, who is also the head of medical business development. They discuss key takeaways for innovation in healthcare, including the importance of embracing failure, solving familiar problems, and cross-pollination across medical disciplines. Dr. Sokumbi shares insights from her journey, emphasizing the value of tenacity and perseverance in bringing novel ideas to market, and touches on the nuances of encouraging diversity in innovation, particularly among women.00:00 Introduction to Dr. Yemi Sokumbi01:47 Defining Innovation in Medicine02:34 Lessons in Innovation and Failure05:25 Applying Innovation Lessons to Parenting07:19 Gender and Innovation10:14 Challenges and Perseverance in Innovation12:53 Final Thoughts on InnovationDr. Olayemi (Yemi) Sokumbi, MD is a dermatologist and dermatopathologist who is currently working at Mayo Clinic in Jacksonville, Florida where she also serves as Medical Director for Business Development. Additionally, she is involved with medical student and resident education in addition to her clinical work. She completed dermatopathology fellowship in 2014 at UT Southwestern Medical Center and was chief resident in dermatology at the Mayo Clinic College of Medicine. She has won numerous awards, including a 2022 Dean's Recognition Diversity & Inclusion Award from the Mayo Clinic Alix School of Medicine, a 2018 Outstanding Medical Student Teacher Award from the Medical College of Wisconsin, and the 2013 Richard K. Winkelmann Excellence in Research Award. 

On this Episode 492 of Health Solutions, Shawn & Janet Needham R. Ph. discuss overuse injuries in athletes and sports with Dr. Shawn E. Johnson. Dr. Johnson has been practicing as an orthopedic surgeon since 2008. She specializes in the treatment of Overuse Injuries, Acute Traumatic Injuries, and Chronic Joint Disorders. Dr. Johnson completed her undergraduate degree at Texas State University. She then obtained her medical degree at UT Southwestern Medical Center at Dallas. After completing her orthopedic surgery residency, she became a staff orthopedic surgeon in the US Army. Dr. Johnson served for nearly 10 years and then completed a Sports Medicine Orthopedic Fellowship at the Ochsner Clinic Foundation. Dr. Johnson has opened her Houston-based private practice, Austin County Orthopedics, and is available for appointments and consultations! 00:00 - Start 00:33 - Dr. Johnson's Introduction 01:09 - Dr. Johnson's Background 05:09 - Overuse Injuries 08:48 - Cross-Training 10:52 - Education 17:06 - Stress Fractures 20:24 - Behave Like an Athlete 21:54 - Staying Involved 24:32 - Anti-Inflammatory 26:28 - Return to Sport 27:23 - Empowering People 29:15 - Medications 30:18 - Alternative Treatments 32:04 - Surgery 38:07 - Dr. Johnson's Passion 42:32 - Dr. Johnson's Contact Information 44:56 - Closing Comments Episode Resources Facebook ~ https://www.facebook.com/austincountyorthopedics Instagram ~ https://www.instagram.com/austin.county.orthopedics/ LinkedIn ~ https://www.linkedin.com/in/shawn-johnson-aa928a183/ Website ~ https://www.drshawnmdortho.com/ EP 492: Athlete Overuse Injuries with Dr. Shawn E. Johnson and Shawn & Janet Needham R. Ph. ~ #athlete #athletic #athletics #sports #sportsinjury #overuse #injury #injuries #medications #pharmaceuticals #pharmaceutical #AustinCountyOrthopedics #directspecialtycare #timewithyoursurgeon #podcastshow #podcast #podcastguest #optimalhealth #healthfreedom #MedicalFreedom #medicaleducation #medicalcare #HealthCare #PriceTransparency #freemarket #Liberty #FitAfter50 #FitOver50 #fitover40 #fitafter40 #Boise #IdahoFalls #Tricities #SiouxFalls #Wenatchee #EducateAndEmpower #NeedhamHealthSolutions #TeamNeedham #ShawnNeedham #HealthSolutions #MosesLakeProfessionalPharmacy #MLRX #SickenedTheBook #ShawnNeedhamRPh #ThinkOutsideTheSystem #OptimalHealthMatters #ItsTime ~ *** #BenShapiro & #DaveRamsey Fans. Learn how to be in the driver's seat for your healthcare choices {not the system or doctors!}

In this episode of the Dr. Geo Podcast, Dr. Geo sits down with Dr. Xiaosong Meng from UT Southwestern Medical Center to discuss TULSA (Transurethral Ultrasound Ablation), an advanced focal treatment for prostate cancer. They explore how TULSA works, its benefits, and how it compares to other focal therapies like HIFU, cryoablation, and IRE. The episode also highlights key factors such as MRI guidance, potential side effects, and the suitability of TULSA for patients with both BPH and prostate cancer.Key Points:Comparison of TULSA with HIFU, cryoablation, and IRE.Importance of MRI guidance and tumor location.Discussion on potential side effects and 'natural' focal therapies.TULSA's suitability for patients with BPH and prostate cancer.Role of TULSA in salvage treatments for recurrent prostate cancer.----------------Tune in for our in-depth 4-part series on Focal and Ablation Therapies, featuring insightful interviews on the latest advancements in treatment.Thank you to our September Sponsors!Focal One- The first and only robotic platform for precise focal ablation using high-intensity focused ultrasound (HIFU). This minimally invasive treatment offers unmatched precision with no surgery, cutting, or radiation, and helps preserve healthy tissue while minimizing side effects. For more details, click [HERE] Profound Medical- TULSA Pro- The innovators behind Tulsa-Pro. Their transurethral ultrasound ablation (TULSA) procedure targets prostate tissue from the inside out through the urethra, reducing risks like erectile dysfunction and incontinence. With real-time MRI and robotics, Tulsa-Pro provides precise, incision-free treatment for effective cancer control. Learn more about Profound Medical and Tulsa-Pro, click [HERE]----------------Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube Channel to get more content like this and learn how you can live better with age.You can also listen to this episode and future episodes of the Dr. Geo Podcast by clicking HERE.----------------Follow Dr. Geo on social media. Facebook, Instagram Click here to become a member of Dr. Geo's Health Community.Improve your urological health with Dr. Geo's formulated supplement lines:XY Wellness for Prostate cancer lifestyle and nutrition: Mr. Happy Nutraceutical Supplements for prostate health and male optimal living.You can also check out Dr. Geo's online dispensary for other supplement recommendations Dr. Geo's Supplement Store____________________________________DISCLAIMER: This audio is educational and does not constitute medical advice. This audio's content is my opinion and not that of my employer(s) or any affiliated company.Use of this information is at your own risk. Geovanni Espinosa, N.D., will not assume any liability for any direct or indirect losses or damages that may result...

This week, we are joined by Dr. Nina Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology Service, UT Southwestern Medical Center in Dallas, Texas, for a discussion about the role of radiation in colorectal cancer, with an emphasis on the role of radiation in rectal cancer. Dr. Sanford is a wealth of knowledge so this is an episode you do NOT want to miss. Of note, rectal cancer episodes will be released in a few weeks so if all of this does not make sense, don't worry. It nicely sets the stage for what is to come! Content: - What is the role of radiation in rectal cancer vs. colon cancer? Why do we use it more in rectal cancer?- How to evaluate your patients for radiation and how to decide long course vs. short course radiation - Side effects of radiation therapy for rectal cancer- Role of radiation for oligmetastatic colorectal cancer** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Today we give you our 19th clinical case and first sport concussion specific case. Nyaz is a neuropsychologist and Associate Professor at UT Southwestern Medical Center. This will be our third conversation with her. We previously discussed chronic traumatic encephalopathy, or CTE, in episode 126, and the 2022 Concussion in Sport Group meeting in episode 127. Show notes are available at www.NavNeuro.com/139 _________________ If you'd like to support the show, here are a few easy ways: 1) Get APA-approved CE credits for listening to select episodes: www.NavNeuro.com/INS  2) Tell your friends and colleagues about it 3) Subscribe (free) and leave an Apple Podcasts rating/review: www.NavNeuro.com/itunes 4) Check out our book Becoming a Neuropsychologist, and leave it an Amazon rating   Thanks for listening, and join us next time as we continue to navigate the brain and behavior! [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners' own risk. Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]